{"id":"valoctocogene-roxaparvovec","rwe":[{"pmid":"41818413","year":"2026","title":"Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels.","finding":"","journal":"Haemophilia : the official journal of the World Federation of Hemophilia","studyType":"Clinical Study"},{"pmid":"41773269","year":"2026","title":"Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.","finding":"","journal":"Journal of blood medicine","studyType":"Clinical Study"},{"pmid":"41709782","year":"2026","title":"Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.","finding":"","journal":"Expert review of hematology","studyType":"Clinical Study"},{"pmid":"41549917","year":"2026","title":"Balancing Promise and Peril: Hemophilia Gene Therapy Insights.","finding":"","journal":"IUBMB life","studyType":"Clinical Study"},{"pmid":"41448545","year":"2026","title":"Overview of gene therapy for hemophilia: questions and answers to navigate the innovation.","finding":"","journal":"Journal of thrombosis and haemostasis : JTH","studyType":"Clinical Study"}],"_fda":{"id":"baada118-a8a4-4c4b-bfd6-dee69373b520","set_id":"0dcf7185-8e1c-456a-9d4e-7cc316400118","openfda":{"unii":["681K1JDI8M"],"route":["INTRAVENOUS"],"rxcui":["2641614","2641620"],"spl_id":["baada118-a8a4-4c4b-bfd6-dee69373b520"],"brand_name":["ROCTAVIAN"],"spl_set_id":["0dcf7185-8e1c-456a-9d4e-7cc316400118"],"package_ndc":["68135-927-01","68135-927-48"],"product_ndc":["68135-927"],"generic_name":["VALOCTOCOGENE ROXAPARVOVEC-RVOX"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["VALOCTOCOGENE ROXAPARVOVEC"],"manufacturer_name":["BioMarin Pharmaceutical Inc."],"application_number":["BLA125720"],"is_original_packager":[true]},"version":"18","pregnancy":["8.1 Pregnancy Risk Summary ROCTAVIAN is not intended for administration in women. There are no data on the use of ROCTAVIAN in pregnant women to inform a drug-associated risk of adverse developmental outcome. Animal reproduction and developmental toxicity studies have not been conducted with ROCTAVIAN. It is not known whether ROCTAVIAN can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the US general population, the estimated background risk of major birth defects occurs in 2 to 4% of the general population and miscarriage occurs in 15 to 20% of clinically recognized pregnancies."],"description":["11 DESCRIPTION ROCTAVIAN (valoctocogene roxaparvovec-rvox) is an adeno-associated virus (AAV) vector-based gene therapy product. ROCTAVIAN is replication-incompetent and consists of an AAV serotype 5 capsid containing a DNA sequence encoding the B-domain deleted SQ form of the human coagulation factor VIII (hFVIII-SQ). ROCTAVIAN is derived from naturally occurring adeno-associated virus and is produced using Sf9 insect cells and recombinant baculovirus technology. ROCTAVIAN is a sterile suspension for intravenous infusion. When thawed, the suspension is clear and colorless to pale yellow. Each vial of ROCTAVIAN contains an extractable volume of 8 mL of valoctocogene roxaparvovec-rvox at a concentration of 2 × 10 13 vector genomes (vg) per mL, and the following excipients: mannitol (20 mg/mL), poloxamer 188 (2.0 mg/mL), sodium chloride (8.2 mg/mL), sodium phosphate monobasic dihydrate (0.23 mg/mL), sodium phosphate dibasic dodecahydrate (3.05 mg/mL) and Water for Injection, USP. The pH of ROCTAVIAN is 6.9 to 7.8. The osmolarity of ROCTAVIAN is 364 to 445 mOsm/L. The product contains no preservative."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied ROCTAVIAN (valoctocogene roxaparvovec-rvox) injection is supplied as a sterile, preservative-free, clear and colorless to pale yellow suspension for intravenous infusion. ROCTAVIAN contains 2 × 10 13 vector genomes (vg) per mL. Each carton of ROCTAVIAN (NDC 68135-927-48) contains one single-dose vial (NDC 68135-927-01) with an extractable volume of not less than 8 mL, containing 16 × 10 13 vector genomes (vg). 16.2 Storage and Handling Product as Packaged for Sale Transport frozen at ≤ -60°C (-76°F) Store upright at ≤ -60°C (-76°F). Store ROCTAVIAN vial in carton until ready to use. Protect ROCTAVIAN from light. During Preparation and Administration Thaw at room temperature, up to 25°C (77°F). After thawing, ROCTAVIAN can be held at room temperature for a maximum of 10 hours, including preparation and infusion times [see Dosage and Administration (2.2) ] . If necessary, an intact vial (stopper not yet punctured) that has been thawed can be stored refrigerated (2 to 8 °C) for up to 3 days, upright and protected from light (e.g., in the original carton). Do not expose ROCTAVIAN to the light of an ultraviolet radiation disinfection lamp. Once thawed, DO NOT REFREEZE. Treat spills of ROCTAVIAN with a virucidal agent with proven activity against non-enveloped viruses and blot using absorbent materials. Dispose of unused product and disposable materials that may have come in contact with ROCTAVIAN in accordance with local guidance for pharmaceutical waste."],"geriatric_use":["8.5 Geriatric Use A single patient ≥ 65 years of age was treated with ROCATVIAN in clinical studies. Clinical studies of ROCTAVIAN did not include sufficient numbers of patients aged 65 and over to determine whether the efficacy or safety differs compared to younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of ROCTAVIAN in pediatric patients have not been established."],"effective_time":"20230629","clinical_studies":["14 CLINICAL STUDIES The efficacy of ROCTAVIAN was evaluated in a prospective, phase 3, open-label, single-dose, single-arm, multinational study in 134 adult males (18 years of age and older) with severe hemophilia A, who received a single intravenous dose of 6 × 10 13 vg/kg body weight of ROCTAVIAN and entered a follow-up period of 5 years. Patients previously treated with prophylactic factor VIII replacement therapy, but not emicizumab, were enrolled in the study. The study population was 72% White, 14% Asian, and 11% Black with a median age of 30 (range: 18 to 70) years. Twenty patients had a history of hepatitis B and 41 patients had a history of hepatitis C. All except 2 patients were HIV-negative. Only patients without detectable, pre-existing antibodies to AAV5 capsid were eligible for therapy. Presence of pre-existing antibodies to AAV5 capsid was identified during screening using the ARUP Laboratories AAV5 DetectCDx ™ total antibody assay, which is the FDA-approved test for selection of patients for ROCTAVIAN therapy. Other key exclusion criteria included active infection, chronic or active hepatitis B or C, immunosuppressive disorder including HIV, current or prior history of factor VIII inhibitor, stage 3 or 4 liver fibrosis, cirrhosis, liver function test abnormalities, history of thrombosis or thrombophilia, serum creatinine ≥ 1.4 mg/dL, and active malignancy. Of the 134 patients who received ROCTAVIAN in the clinical trial, 112 patients had baseline annualized bleeding rate (ABR) data prospectively collected during a period of at least six months on factor VIII prophylaxis prior to receiving ROCTAVIAN (rollover population). The remaining 22 patients had baseline ABR collected retrospectively (directly enrolled population). All patients were followed for at least 3 years. The primary efficacy outcome was a non-inferiority (NI) test of the difference in ABR in the efficacy evaluation period (EEP) following ROCTAVIAN administration compared with ABR during the baseline period in the rollover population. The NI margin was 3.5 bleeds per year. All bleeding episodes, regardless of treatment, were counted towards ABR. The EEP started from Study Day 33 (Week 5) or the end of factor VIII prophylaxis including a washout period after ROCTAVIAN treatment, whichever was later, and ended when a patient completed the study, had the last visit, or withdrew or was lost to follow-up from the study, whichever was the earliest. Table 9 summarizes the NI comparison between the mean ABR after ROCTAVIAN treatment and the mean baseline ABR while patients were on factor VIII prophylaxis in the rollover population (N = 112). The mean EEP ABR was 2.6 bleeds/year, compared to a mean baseline ABR of 5.4 bleeds/year. The mean difference in ABR was -2.8 (95% confidence interval: -4.3, -1.2) bleeds/year. The NI analysis met the pre-specified NI margin, indicating the effectiveness of ROCTAVIAN. A majority of patients treated with ROCTAVIAN received immunosuppressive medications, including steroids, to control elevations in transaminases and to prevent loss of transgene expression [see Dosage and Administration (2.3) , Warnings and Precautions (5.2) , and Adverse Reactions (6.1) ] . Table 9: Summary of ABRs and Bleeding Events (Rollover Population, N = 112) ABR and Bleeding Events Baseline Post-ROCTAVIAN Efficacy Evaluation Period Min: Minimum; Max: Maximum; SD: Standard Deviation Median (range) follow-up duration in years 0.6 (0.5, 1.3) 3.0 (1.7, 3.7) Follow-up duration in person-years 78.3 342.8 Mean (SD) ABR in bleeds/year 5.4 (6.9) 2.6 (6.2) A total of 13 patients (12%) had used factor VIII replacement products or emicizumab during the efficacy evaluation period for prophylaxis, with a median start time at 2.3 (range: 0.1 to 3.3) years. An ABR of 35 was imputed for the periods when these patients were on prophylaxis. Median (min, max) ABR in bleeds/year 3.3 (0, 34.6) 0.3 (0, 35.0) Observed spontaneous bleed count (proportion of total bleeds) 176 (42%) 179 (41%) Observed joint bleed count (proportion of total bleeds) 240 (57%) 195 (45%) In the rollover population, a total of 5 patients (4%) did not respond and 17 patients (15%) lost response to ROCTAVIAN treatment over a median time of 2.3 (range: 1.0 to 3.3) years. In the directly enrolled population with a longer follow-up, a total of 1 patient (5%) did not respond and 6 patients (27%) lost response to ROCTAVIAN treatment over a median time of 3.6 (range: 1.2 to 4.3) years."],"pharmacodynamics":["12.2 Pharmacodynamics Following ROCTAVIAN infusion, vector DNA is processed in vivo to form full-length, episomal transgenes that increase circulating hFVIII-SQ up to 5 years. Liver samples from 5 patients in clinical studies collected 0.5-4.1 years post-dose were analyzed. Vector integration into human genomic DNA was observed in all samples. No preferential integration of the vector and no clonal outgrowth of cells as a result of vector integration was observed. ROCTAVIAN can also insert into DNA of other human body cells; vector insertion into parotid gland DNA samples without associated clinical manifestations was observed in one patient treated with ROCTAVIAN . Factor VIII Activity The pharmacodynamic effect of ROCTAVIAN was assessed by measuring circulating factor VIII activity levels. Factor VIII activity levels (IU/dL) over time post-ROCTAVIAN infusion in ITT population are reported by both the CSA and OSA. The mean factor VIII activity levels at Month 36 was 18.2 IU/dL (95% CI: 12.9, 23.4) using the CSA, a statistically significant (p < 0.0001) improvement from 1 IU/dL at baseline. Table 7 shows factor VIII activity levels (IU/dL) over time post-ROCTAVIAN infusion in patients rolled over from a non-interventional study prospectively collecting patients' baseline annualized bleeding rate (ABR) and factor VIII usage data. Table 7: Factor VIII Activity Levels (IU/dL) Over Time Timepoint Rollover Population N = 112 Directly Enrolled Population N = 22 CSA OSA CSA OSA Month 3 N = 111 N = 111 N = 22 N = 22 Mean (SD) 34.9 (40.4) 54.6 (60.8) 31.4 (25.7) 48.3 (36.0) Median (Q1, Q3) 20.7 (10.3, 40.5) 31.3 (15.3, 71.7) 20.9 (12.6, 45.7) 36.0 (22.4, 63.9) Min, Max 0, 249.5 1.5, 335.8 0, 85.8 4.5, 126.0 Month 6 N = 111 N = 111 N = 22 N = 22 Mean (SD) 55.4 (57.5) 84.9 (83.1) 40.0 (37.9) 63.0 (57.2) Median (Q1, Q3) 38.8 (16.8, 76.5) 62.0 (28.0, 115.2) 33.2 (14.7, 46.3) 53.5 (23.7, 78.2) Min, Max 0, 367.3 1.9, 483.9 0, 169.4 1.8, 261.9 Month 10 N = 111 N = 111 N = 20 N = 20 Mean (SD) 49.4 (49.5) 73.6 (70.5) 44.2 (49.6) 70.2 (70.9) Median (Q1, Q3) 31.7 (17.1, 64.5) 51.3 (25.1, 96.2) 30.9 (14.1, 68.6) 55.4 (24.8, 101.4) Min, Max 0, 265.3 1.2, 375.6 0, 223.6 2.4, 313.7 Month 12 N = 111 N = 111 N = 21 N = 21 Mean (SD) 43.6 (45.5) 64.7 (64.6) 38.2 (46.3) 59.7 (67.0) Median (Q1, Q3) 24.0 (12.5, 63.7) 40.0 (20.4, 87.5) 23.9 (11.2, 52.8) 40.5 (17.4, 82.6) Min, Max 0, 231.2 0, 311.1 1.6, 207.4 4.4, 294.1 Month 18 N = 99 N = 99 N = 18 N = 18 Mean (SD) 27.7 (32.3) 40.6 (45.9) 28.5 (28.9) 44.5 (43.9) Median (Q1, Q3) 13.5 (6.9, 36.8) 22.5 (10.9, 55.30) 15.3 (10.8, 43.9) 24.4 (17.7, 60.4) Min, Max 0, 167.9 0, 232.2 3.3, 117.0 4.2, 173.7 Month 24 N = 98 N = 99 N = 19 N = 18 Mean (SD) 25.0 (35.5) 38.9 (50.7) 22.0 (28.7) 36.0 (40.8) Median (Q1, Q3) 12.7 (5.1, 26.5) 22.7 (7.9, 45.7) 8.9 (5.8, 25.9) 19.5 (7.9, 37.7) Min, Max 0, 187.1 0, 271.3 0, 110.6 2.4, 146.7 Month 36 N = 96 N = 97 N = 15 N = 15 Mean (SD) 21.0 (34.0) 33.8 (47.6) 20.8 (24.4) 32.2 (33.1) Median (Q1, Q3) 10.0 (4.3, 19.8) 17.7 (7.2, 35.1) 9.4 (6.6, 31.7) 20.6 (8.5, 46.7) Min, Max 0, 217.7 0, 291.4 0, 74.5 1.9, 104.2 The proportion of patients achieving factor VIII activity level thresholds by year are presented in Table 8 by both the CSA and OSA. The majority (95%) of patients who reach factor VIII activity levels of ≥ 5 IU/dL using the CSA do so within 5 months post-infusion. Table 8: Patients Achieving Factor VIII Activity Thresholds by Year Rollover Population (N = 112) Factor VIII Activity Threshold Achieved by Assay Year 1 N = 111 n (%) Year 2 N = 98 n (%) Year 3 N = 96 n (%) CSA > 150 IU/dL 6 (5%) 2 (2%) 2 (2%) 40 - ≤ 150 IU/dL 37 (33%) 14 (14%) 9 (9%) 15 - < 40 IU/dL 37 (33%) 27 (28%) 23 (24%) 5 - < 15 IU/dL 18 (16%) 33 (34%) 35 (36%) 3 - < 5 IU/dL 3 (3%) 10 (10%) 8 (8%) < 3 IU/dL 10 (9%) 12 (12%) 19 (20%) Year 1 N = 111 n (%) Year 2 N = 99 n (%) Year 3 N = 97 n (%) OSA > 150 IU/dL 12 (11%) 5 (5%) 4 (4%) 40 - ≤ 150 IU/dL 44 (40%) 25 (25%) 17 (18%) 15 - < 40 IU/dL 37 (33%) 36 (36%) 36 (37%) 5 - < 15 IU/dL 10 (9%) 20 (20%) 26 (27%) 1 - < 5 IU/dL 6 (5%) 11 (11%) 12 (12%) < 1 IU/dL 2 (2%) 2 (2%) 2 (2%) Directly Enrolled Population (N = 22) Factor VIII Activity Threshold Achieved by Assay Year 1 N = 21 n (%) Year 2 N = 19 n (%) Year 3 N = 15 n (%) CSA > 150 IU/dL 1 (5%) 0 (0%) 0 (0%) 40 - ≤ 150 IU/dL 5 (24%) 3 (16%) 3 (20%) 15 - < 40 IU/dL 8 (38%) 4 (21%) 2 (13%) 5 - < 15 IU/dL 5 (24%) 8 (42%) 7 (47%) 3 - < 5 IU/dL 0 (0%) 1 (5%) 1 (7%) < 3 IU/dL 2 (10%) 3 (16%) 2 (13%) Year 1 N = 21 n (%) Year 2 N = 18 n (%) Year 3 N = 15 n (%) OSA > 150 IU/dL 1 (5%) 0 (0%) 0 (0%) 40 - ≤ 150 IU/dL 10 (48%) 4 (22%) 4 (27%) 15 - < 40 IU/dL 6 (29%) 6 (33%) 6 (40%) 5 - < 15 IU/dL 3 (14%) 6 (33%) 3 (20%) 1 - < 5 IU/dL 1 (5%) 2 (11%) 2 (13%) < 1 IU/dL 0 (0%) 0 (0%) 0 (0%) Specific Populations A trend of lower factor VIII activity levels was observed in Black patients within the study population. The mean (SD) peak factor VIII activity levels measured by chromogenic assay were 37.2 (27.5) IU/dL and 90.8 (84.5) IU/dL for Black patients and patients of other races (Asian, White and others). Given the small sample size, the limited number of sites enrolling Black patients relative to the total population, the existence of potential confounding factors, and multiple posthoc analyses, this trend was insufficient to allow meaningful conclusions about the differences in response rates based on race or other factors therein influencing factor VIII expression following ROCTAVIAN infusion. Despite differences in factor VIII activity levels, ABR and annualized factor VIII usage was similar across races."],"pharmacokinetics":["12.3 Pharmacokinetics Biodistribution (within the body) and Vector Shedding (excretion/secretion) Valoctocogene roxaparvovec-rvox transgene DNA levels (total amount of vector DNA) in various tissues (evaluated in nonclinical studies), blood, and shedding matrices were determined using a quantitative polymerase chain reaction (qPCR) assay. This assay is sensitive to transgene DNA, including fragments of degraded DNA. It does not indicate whether DNA is present in the vector capsid, in cells or in the fluid phase of the matrix (e.g., blood plasma, seminal fluid), or whether intact vector is present. Plasma and semen matrices were further evaluated by measuring encapsidated (potentially infectious) vector DNA using an immunoprecipitation quantitative PCR assay in Studies 270-201 and 270-301. Nonclinical Data Biodistribution of ROCTAVIAN was assessed in adult male mice. Following intravenous administration of 2.1 × 10 14 vg/kg, the highest vector DNA concentration was detected in the liver, followed by lower levels in the lung, heart, lymph nodes, kidney, spleen, bone marrow, testis, and brain through six months post-administration. The expression of the hFVIII mRNA transcripts were primarily detected in the liver, with no or minimal expression in extrahepatic tissues. Clinical Data ROCTAVIAN biodistribution and vector shedding were investigated on samples from blood, saliva, semen, stool, and urine. Administration of ROCTAVIAN at the dose of 6 × 10 13 vg/kg resulted in detectable vector DNA in blood and all shedding matrices evaluated at the dose of 6 × 10 13 vg/kg, with peak concentrations observed between 1 and 9 days post-administration. The peak vector DNA concentrations were observed in blood, followed by saliva, semen, stool, and urine. The peak concentration observed to date in blood across two clinical studies was 2 × 10 11 vg/mL. The maximum concentration observed in any shedding matrix was 1 × 10 10 vg/mL. After reaching the maximum in a matrix, the transgene DNA concentration declines steadily. In patients treated in two clinical studies, encapsidated (potentially transmissible) vector DNA was detectable in plasma up to 10 weeks after ROCTAVIAN administration. All patients treated in clinical studies achieved the first of 3 consecutive measurements below the lower limit of quantification (LLOQ) for vector DNA in semen by 36 weeks, and all except one patient achieved 3 consecutive measurements below limit of detection (BLOD) or negative by the time of the data cut. The maximum time to the first of 3 consecutive measurements BLOD for encapsidated (potentially transmissible) vector DNA in semen was 12 weeks. In clinical studies, all patients achieved 3 consecutive measurements below the LLOQ for vector DNA in urine and saliva, and 126 (89%) patients achieved 3 consecutive measurements below the LLOQ for vector DNA in stool by the time of the data cut. The maximum time to the first of 3 consecutive LLOQ measurements was 8 weeks for urine, 52 weeks for saliva, and 131 weeks for stool. All patients in the first study achieved 3 consecutive measurements BLOD or negative in urine, saliva, and stool by five-year post-dosing. All patients in the second study achieved 3 consecutive measurements BLOD or negative in urine, and saliva, and 85 (63%) patients achieved 3 consecutive measurements BLOD or negative in stool by three-year data cut. Magnitude and duration of shedding appear to be independent of the patient's attained factor VIII activity."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are also discussed in other sections of the label: Infusion-Related Reactions [see Warnings and Precautions (5.1) ] Hepatotoxicity [see Warnings and Precautions (5.2) ] Most common adverse reactions (incidence ≥ 5%) were nausea, fatigue, headache, infusion-related reactions, vomiting, and abdominal pain. ( 6 ) Most common laboratory abnormalities (incidence ≥ 10%) were ALT, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), factor VIII activity levels, gamma-glutamyl transferase (GGT) and bilirubin > ULN. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact BioMarin Pharmaceutical Inc. at 1-866-906-6100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described in this section reflect the exposure of 134 adult patients with severe hemophilia A (defined as residual factor VIII activity ≤ 1 IU/dL) to a single dose of 6 × 10 13 vg/kg of body weight of ROCTAVIAN. Patients with detectable pre-existing antibodies to AAV5, active infections, history of thrombosis, immunosuppressive disorders, and liver dysfunction were excluded. All patients had a median follow-up of 162 weeks (range: 66 to 255 weeks) [see Clinical Studies (14) ] . The most common adverse reactions (≥ 5%) to ROCTAVIAN were nausea, fatigue, headache, infusion-related reactions, vomiting, and abdominal pain. The most common laboratory abnormalities (≥ 10%) to ROCTAVIAN were ALT, AST, LDH, CPK, factor VIII activity levels, GGT, and bilirubin > ULN. Non-laboratory adverse reactions (≥ 5%) to ROCTAVIAN are listed in Table 5. There were 6 serious adverse reactions related to ROCTAVIAN treatment including ALT elevation, presyncope, maculopapular rash, anaphylaxis, and hypersensitivity reaction. Table 5: Adverse Reactions in ≥ 5% Other adverse reactions include gastroenteritis (2 patients; 1%), rash (2 patients; 1%), diarrhea (6 patients; 4%), and dizziness (3 patients; 2%). of Patients Treated with ROCTAVIAN Adverse Reactions Number of Patients (%) N = 134 All Grades ≥ Grade 3 Nervous system disorders Headache 9 (7%) 0 (0%) Gastrointestinal disorders Nausea 42 (31%) 0 (0%) Vomiting 8 (6%) 0 (0%) Abdominal pain Includes abdominal discomfort, abdominal distension, abdominal tenderness, and abdominal pain upper. 8 (6%) 0 (0%) General disorders and administration site conditions Fatigue Includes fatigue, lethargy, and malaise. 21 (16%) 0 (0%) Infusion-related reactions Infusion-related reactions are not under a specific system organ class and include multiple symptoms that occurred during or within 6 hours after the end of infusion [see Warnings and Precautions (5.1) ]. 9 (7%) 2 (1%) Table 6 lists laboratory abnormalities in patients treated with ROCTAVIAN. Table 6: Laboratory Abnormalities in Patients Treated with ROCTAVIAN Laboratory Abnormalities Number of Patients (%) N = 134 ALT increases > ULN 109 (81%) AST increases > ULN 92 (69%) LDH increases > ULN 77 (57%) CPK increases > ULN 60 (45%) Factor VIII activity levels > ULN Patients with one or more instances of factor VIII activity levels > 170 IU/dL (ULN of the CSA used) or > 150 IU/dL (ULN of the OSA used) [see Warnings and Precautions (5.3) ] . 38 (28%) GGT increases > ULN 24 (18%) Bilirubin increases > ULN 18 (13%) Twelve (9%), 9 (7%) and 1 (1%) of patients experienced > 5-20 × ULN ALT, AST and GGT elevations, respectively. Seven (5%) patients and 5 (4%) patients experienced > 5-10 × ULN and > 10 × ULN CPK increases, respectively. Infusion-related reactions were observed in 9 patients (7%), including hypersensitivity reactions (4%) and anaphylaxis (1%), and have occurred during and/or following ROCTAVIAN administration. Hepatotoxicity as defined by ALT ≥ 1.5 × baseline or ALT > ULN occurred in 107 of 112 (96%) patients. Nine (8%) patients had ALT between > 5-20 × ULN. One hundred (89%) patients had ALT elevations that occurred within the first 26 weeks, 74 (66%) patients had ALT elevations that occurred between weeks 27 to 52, and 72 (64%) patients had ALT elevations that occurred beyond 52 weeks after administration. Thirty-four of 112 (30%) patients had ALT elevations that were associated with a decline in factor VIII activity of ≥ 30%. The majority of patients (82%, 92/112) required corticosteroids for one or more episodes of ALT elevation while 35% (39/112) required alternate immunosuppression. Seventy-six percent, 5%, and 1% of patients used corticosteroids within the first 26 weeks, weeks 27 to 52, and beyond 52 weeks respectively following ROCTAVIAN administration. The most common (≥ 10%) adverse reactions from corticosteroid use (N = 92) included acne (34%), insomnia (27%), mood disorders (20%), cushingoid (20%), rash (18%), weight gain (16%), hypertension (12%), folliculitis (11%), abdominal pain (10%), and vision disorders (10%). Other clinically meaningful adverse events while on corticosteroid therapy included bone fracture (5%), impaired glucose tolerance (5%), herpes zoster (3%), oral candidiasis (3%), and adrenal insufficiency (1%). The most common adverse reactions from alternate immunosuppressant use (N = 39) included hypomagnesemia (15%) and diarrhea (10%). Infections requiring intravenous antimicrobial therapy occurred in 3 (3%) patients while on corticosteroid or other immunosuppressant therapy (N = 97). One case of autoimmune hepatitis was reported during third year follow-up in a patient with history of hepatitis C and steatohepatitis."],"contraindications":["4 CONTRAINDICATIONS Administration of ROCTAVIAN is contraindicated in: patients with active infections, either acute (such as acute respiratory infections or acute hepatitis) or uncontrolled chronic (such as chronic active hepatitis B) . patients with known significant hepatic fibrosis (stage 3 or 4 on the Batts-Ludwig scale or equivalent), or cirrhosis [see Dosage and Administration (2) ]. patients with known hypersensitivity to mannitol. Active infections, either acute or uncontrolled chronic. ( 4 ) Known significant hepatic fibrosis (stage 3 or 4), or cirrhosis. ( 4 ) Known hypersensitivity to mannitol. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patient's existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patient's hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e.g., weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7.1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to < 3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week 72, factor VIII activity recovered to 46 IU/dL at Week 122. An in vitro study in human primary hepatocytes indicated that isotretinoin suppressed factor VIII transcription independent of hepatotoxicity, without impact on ALT, and expression was partially restored upon cessation of isotretinoin treatment. Isotretinoin is not recommended in patients who are benefiting from ROCTAVIAN. 7.2 Efavirenz One HIV positive patient treated with ROCTAVIAN at a dose of 4 × 10 13 vg/kg ROCTAVIAN while on an antiretroviral therapy regimen consisting of efavirenz, lamivudine, and tenofovir experienced asymptomatic elevations of ALT, AST, and GGT (> 5.0 × ULN) and serum bilirubin (> ULN and up to 1.5 × ULN) at Week 4 [see Use in Specific Populations (8.6) ] . The reaction resolved after the antiretroviral therapy regimen was changed to a regimen without efavirenz. The patient later reverted to prophylactic use of factor VIII concentrates. An in vitro study in human primary hepatocytes indicated that efavirenz suppressed factor VIII transcription independent of hepatotoxicity, and expression was not restored upon discontinuation of efavirenz. Efavirenz is not recommended in patients treated with ROCTAVIAN. 7.3 Interactions with Agents that May Reduce or Increase Plasma Concentrations of Corticosteroids Agents that may reduce or increase the plasma concentration of corticosteroids (e.g., agents that induce or inhibit cytochrome P450 3A4) can decrease the efficacy of the corticosteroid regimen or increase their side effects [see Dosage and Administration (2.3) ] . 7.4 Vaccinations Prior to ROCTAVIAN infusion, ensure up to date vaccinations. Individual vaccination schedules may need to be adjusted to accommodate concomitant immunosuppressive therapy [see Dosage and Administration (2.3) ] . Live vaccines should not be administered to patients while on immunosuppressive therapy."],"mechanism_of_action":["12.1 Mechanism of Action Valoctocogene roxaparvovec-rvox is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector, designed to introduce a functional copy of a transgene encoding the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). Transcription of this transgene occurs within the liver, using a liver-specific promoter, which results in the expression of hFVIII-SQ. The expressed hFVIII-SQ replaces the missing coagulation factor VIII needed for effective hemostasis."],"storage_and_handling":["16.2 Storage and Handling Product as Packaged for Sale Transport frozen at ≤ -60°C (-76°F) Store upright at ≤ -60°C (-76°F). Store ROCTAVIAN vial in carton until ready to use. Protect ROCTAVIAN from light. During Preparation and Administration Thaw at room temperature, up to 25°C (77°F). After thawing, ROCTAVIAN can be held at room temperature for a maximum of 10 hours, including preparation and infusion times [see Dosage and Administration (2.2) ] . If necessary, an intact vial (stopper not yet punctured) that has been thawed can be stored refrigerated (2 to 8 °C) for up to 3 days, upright and protected from light (e.g., in the original carton). Do not expose ROCTAVIAN to the light of an ultraviolet radiation disinfection lamp. Once thawed, DO NOT REFREEZE. Treat spills of ROCTAVIAN with a virucidal agent with proven activity against non-enveloped viruses and blot using absorbent materials. Dispose of unused product and disposable materials that may have come in contact with ROCTAVIAN in accordance with local guidance for pharmaceutical waste."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Valoctocogene roxaparvovec-rvox is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector, designed to introduce a functional copy of a transgene encoding the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). Transcription of this transgene occurs within the liver, using a liver-specific promoter, which results in the expression of hFVIII-SQ. The expressed hFVIII-SQ replaces the missing coagulation factor VIII needed for effective hemostasis. 12.2 Pharmacodynamics Following ROCTAVIAN infusion, vector DNA is processed in vivo to form full-length, episomal transgenes that increase circulating hFVIII-SQ up to 5 years. Liver samples from 5 patients in clinical studies collected 0.5-4.1 years post-dose were analyzed. Vector integration into human genomic DNA was observed in all samples. No preferential integration of the vector and no clonal outgrowth of cells as a result of vector integration was observed. ROCTAVIAN can also insert into DNA of other human body cells; vector insertion into parotid gland DNA samples without associated clinical manifestations was observed in one patient treated with ROCTAVIAN . Factor VIII Activity The pharmacodynamic effect of ROCTAVIAN was assessed by measuring circulating factor VIII activity levels. Factor VIII activity levels (IU/dL) over time post-ROCTAVIAN infusion in ITT population are reported by both the CSA and OSA. The mean factor VIII activity levels at Month 36 was 18.2 IU/dL (95% CI: 12.9, 23.4) using the CSA, a statistically significant (p < 0.0001) improvement from 1 IU/dL at baseline. Table 7 shows factor VIII activity levels (IU/dL) over time post-ROCTAVIAN infusion in patients rolled over from a non-interventional study prospectively collecting patients' baseline annualized bleeding rate (ABR) and factor VIII usage data. Table 7: Factor VIII Activity Levels (IU/dL) Over Time Timepoint Rollover Population N = 112 Directly Enrolled Population N = 22 CSA OSA CSA OSA Month 3 N = 111 N = 111 N = 22 N = 22 Mean (SD) 34.9 (40.4) 54.6 (60.8) 31.4 (25.7) 48.3 (36.0) Median (Q1, Q3) 20.7 (10.3, 40.5) 31.3 (15.3, 71.7) 20.9 (12.6, 45.7) 36.0 (22.4, 63.9) Min, Max 0, 249.5 1.5, 335.8 0, 85.8 4.5, 126.0 Month 6 N = 111 N = 111 N = 22 N = 22 Mean (SD) 55.4 (57.5) 84.9 (83.1) 40.0 (37.9) 63.0 (57.2) Median (Q1, Q3) 38.8 (16.8, 76.5) 62.0 (28.0, 115.2) 33.2 (14.7, 46.3) 53.5 (23.7, 78.2) Min, Max 0, 367.3 1.9, 483.9 0, 169.4 1.8, 261.9 Month 10 N = 111 N = 111 N = 20 N = 20 Mean (SD) 49.4 (49.5) 73.6 (70.5) 44.2 (49.6) 70.2 (70.9) Median (Q1, Q3) 31.7 (17.1, 64.5) 51.3 (25.1, 96.2) 30.9 (14.1, 68.6) 55.4 (24.8, 101.4) Min, Max 0, 265.3 1.2, 375.6 0, 223.6 2.4, 313.7 Month 12 N = 111 N = 111 N = 21 N = 21 Mean (SD) 43.6 (45.5) 64.7 (64.6) 38.2 (46.3) 59.7 (67.0) Median (Q1, Q3) 24.0 (12.5, 63.7) 40.0 (20.4, 87.5) 23.9 (11.2, 52.8) 40.5 (17.4, 82.6) Min, Max 0, 231.2 0, 311.1 1.6, 207.4 4.4, 294.1 Month 18 N = 99 N = 99 N = 18 N = 18 Mean (SD) 27.7 (32.3) 40.6 (45.9) 28.5 (28.9) 44.5 (43.9) Median (Q1, Q3) 13.5 (6.9, 36.8) 22.5 (10.9, 55.30) 15.3 (10.8, 43.9) 24.4 (17.7, 60.4) Min, Max 0, 167.9 0, 232.2 3.3, 117.0 4.2, 173.7 Month 24 N = 98 N = 99 N = 19 N = 18 Mean (SD) 25.0 (35.5) 38.9 (50.7) 22.0 (28.7) 36.0 (40.8) Median (Q1, Q3) 12.7 (5.1, 26.5) 22.7 (7.9, 45.7) 8.9 (5.8, 25.9) 19.5 (7.9, 37.7) Min, Max 0, 187.1 0, 271.3 0, 110.6 2.4, 146.7 Month 36 N = 96 N = 97 N = 15 N = 15 Mean (SD) 21.0 (34.0) 33.8 (47.6) 20.8 (24.4) 32.2 (33.1) Median (Q1, Q3) 10.0 (4.3, 19.8) 17.7 (7.2, 35.1) 9.4 (6.6, 31.7) 20.6 (8.5, 46.7) Min, Max 0, 217.7 0, 291.4 0, 74.5 1.9, 104.2 The proportion of patients achieving factor VIII activity level thresholds by year are presented in Table 8 by both the CSA and OSA. The majority (95%) of patients who reach factor VIII activity levels of ≥ 5 IU/dL using the CSA do so within 5 months post-infusion. Table 8: Patients Achieving Factor VIII Activity Thresholds by Year Rollover Population (N = 112) Factor VIII Activity Threshold Achieved by Assay Year 1 N = 111 n (%) Year 2 N = 98 n (%) Year 3 N = 96 n (%) CSA > 150 IU/dL 6 (5%) 2 (2%) 2 (2%) 40 - ≤ 150 IU/dL 37 (33%) 14 (14%) 9 (9%) 15 - < 40 IU/dL 37 (33%) 27 (28%) 23 (24%) 5 - < 15 IU/dL 18 (16%) 33 (34%) 35 (36%) 3 - < 5 IU/dL 3 (3%) 10 (10%) 8 (8%) < 3 IU/dL 10 (9%) 12 (12%) 19 (20%) Year 1 N = 111 n (%) Year 2 N = 99 n (%) Year 3 N = 97 n (%) OSA > 150 IU/dL 12 (11%) 5 (5%) 4 (4%) 40 - ≤ 150 IU/dL 44 (40%) 25 (25%) 17 (18%) 15 - < 40 IU/dL 37 (33%) 36 (36%) 36 (37%) 5 - < 15 IU/dL 10 (9%) 20 (20%) 26 (27%) 1 - < 5 IU/dL 6 (5%) 11 (11%) 12 (12%) < 1 IU/dL 2 (2%) 2 (2%) 2 (2%) Directly Enrolled Population (N = 22) Factor VIII Activity Threshold Achieved by Assay Year 1 N = 21 n (%) Year 2 N = 19 n (%) Year 3 N = 15 n (%) CSA > 150 IU/dL 1 (5%) 0 (0%) 0 (0%) 40 - ≤ 150 IU/dL 5 (24%) 3 (16%) 3 (20%) 15 - < 40 IU/dL 8 (38%) 4 (21%) 2 (13%) 5 - < 15 IU/dL 5 (24%) 8 (42%) 7 (47%) 3 - < 5 IU/dL 0 (0%) 1 (5%) 1 (7%) < 3 IU/dL 2 (10%) 3 (16%) 2 (13%) Year 1 N = 21 n (%) Year 2 N = 18 n (%) Year 3 N = 15 n (%) OSA > 150 IU/dL 1 (5%) 0 (0%) 0 (0%) 40 - ≤ 150 IU/dL 10 (48%) 4 (22%) 4 (27%) 15 - < 40 IU/dL 6 (29%) 6 (33%) 6 (40%) 5 - < 15 IU/dL 3 (14%) 6 (33%) 3 (20%) 1 - < 5 IU/dL 1 (5%) 2 (11%) 2 (13%) < 1 IU/dL 0 (0%) 0 (0%) 0 (0%) Specific Populations A trend of lower factor VIII activity levels was observed in Black patients within the study population. The mean (SD) peak factor VIII activity levels measured by chromogenic assay were 37.2 (27.5) IU/dL and 90.8 (84.5) IU/dL for Black patients and patients of other races (Asian, White and others). Given the small sample size, the limited number of sites enrolling Black patients relative to the total population, the existence of potential confounding factors, and multiple posthoc analyses, this trend was insufficient to allow meaningful conclusions about the differences in response rates based on race or other factors therein influencing factor VIII expression following ROCTAVIAN infusion. Despite differences in factor VIII activity levels, ABR and annualized factor VIII usage was similar across races. 12.3 Pharmacokinetics Biodistribution (within the body) and Vector Shedding (excretion/secretion) Valoctocogene roxaparvovec-rvox transgene DNA levels (total amount of vector DNA) in various tissues (evaluated in nonclinical studies), blood, and shedding matrices were determined using a quantitative polymerase chain reaction (qPCR) assay. This assay is sensitive to transgene DNA, including fragments of degraded DNA. It does not indicate whether DNA is present in the vector capsid, in cells or in the fluid phase of the matrix (e.g., blood plasma, seminal fluid), or whether intact vector is present. Plasma and semen matrices were further evaluated by measuring encapsidated (potentially infectious) vector DNA using an immunoprecipitation quantitative PCR assay in Studies 270-201 and 270-301. Nonclinical Data Biodistribution of ROCTAVIAN was assessed in adult male mice. Following intravenous administration of 2.1 × 10 14 vg/kg, the highest vector DNA concentration was detected in the liver, followed by lower levels in the lung, heart, lymph nodes, kidney, spleen, bone marrow, testis, and brain through six months post-administration. The expression of the hFVIII mRNA transcripts were primarily detected in the liver, with no or minimal expression in extrahepatic tissues. Clinical Data ROCTAVIAN biodistribution and vector shedding were investigated on samples from blood, saliva, semen, stool, and urine. Administration of ROCTAVIAN at the dose of 6 × 10 13 vg/kg resulted in detectable vector DNA in blood and all shedding matrices evaluated at the dose of 6 × 10 13 vg/kg, with peak concentrations observed between 1 and 9 days post-administration. The peak vector DNA concentrations were observed in blood, followed by saliva, semen, stool, and urine. The peak concentration observed to date in blood across two clinical studies was 2 × 10 11 vg/mL. The maximum concentration observed in any shedding matrix was 1 × 10 10 vg/mL. After reaching the maximum in a matrix, the transgene DNA concentration declines steadily. In patients treated in two clinical studies, encapsidated (potentially transmissible) vector DNA was detectable in plasma up to 10 weeks after ROCTAVIAN administration. All patients treated in clinical studies achieved the first of 3 consecutive measurements below the lower limit of quantification (LLOQ) for vector DNA in semen by 36 weeks, and all except one patient achieved 3 consecutive measurements below limit of detection (BLOD) or negative by the time of the data cut. The maximum time to the first of 3 consecutive measurements BLOD for encapsidated (potentially transmissible) vector DNA in semen was 12 weeks. In clinical studies, all patients achieved 3 consecutive measurements below the LLOQ for vector DNA in urine and saliva, and 126 (89%) patients achieved 3 consecutive measurements below the LLOQ for vector DNA in stool by the time of the data cut. The maximum time to the first of 3 consecutive LLOQ measurements was 8 weeks for urine, 52 weeks for saliva, and 131 weeks for stool. All patients in the first study achieved 3 consecutive measurements BLOD or negative in urine, saliva, and stool by five-year post-dosing. All patients in the second study achieved 3 consecutive measurements BLOD or negative in urine, and saliva, and 85 (63%) patients achieved 3 consecutive measurements BLOD or negative in stool by three-year data cut. Magnitude and duration of shedding appear to be independent of the patient's attained factor VIII activity. 12.6 Immunogenicity The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of ROCTAVIAN or of other adeno-associated virus-based gene therapy products. In clinical studies, all patients receiving treatment were required to screen negative for anti-AAV5 antibodies and negative (< 0.6 BU) for factor VIII inhibitors in a Nijmegen modified Bethesda assay following a lifetime minimum of 150 exposure days to factor VIII replacement therapy [see Use in Specific Populations (8.7) ] . Following infusion of ROCTAVIAN, all patients remained negative for factor VIII inhibitors. All patients seroconverted to anti-AAV5 antibody positive within 8 weeks of administration. Anti-AAV5 total antibody titers peaked by 36 weeks after administration with mean (SD) values of 12,528,983 (32,427,817), and remained stable until the last time point tested, Week 168 with mean (SD) values of 3,673,038 (3,344,713). ROCTAVIAN-treated patients were tested for cellular immune responses against the AAV5 capsid and the factor VIII transgene product using an IFN-γ ELISpot assay. AAV5 capsid-specific cellular immune responses were detected beginning at Week 2 following dose administration and often declined or reverted to negative over the first 52 weeks in the majority of patients with available data. Incidence peaked at Week 2 with 67 of 96 patients (70%) testing positive in the IFN-γ ELISpot assay. This declined to 17 of 74 patients (23%) at Week 26, and 10 of 60 patients (17%) at Week 52. Factor VIII-specific cellular responses were detected in 81 of 123 (65.9%) patients, often sporadically at a single time point and reverting to negative in most patients."],"indications_and_usage":["1 INDICATIONS AND USAGE ROCTAVIAN is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test. ROCTAVIAN is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Infusion-related reactions: Infusion reactions, including hypersensitivity reactions and anaphylaxis, have occurred. Monitor during and for at least 3 hours after ROCTAVIAN administration. If symptoms occur, slow or interrupt administration and give appropriate treatment. Restart infusion at slower rate once symptoms resolve. Discontinue infusion for anaphylaxis. ( 2.3 , 5.1 ) Hepatotoxicity: Monitor alanine aminotransferase (ALT) weekly for at least 26 weeks and institute corticosteroid treatment in response to ALT elevations as required. Continue to monitor ALT until it returns to baseline. Monitor factor VIII activity levels since ALT elevation may be accompanied by a decrease in factor VIII activity. Monitor for and manage adverse reactions from corticosteroid use. ( 5.2 ) Thromboembolic events: Thromboembolic events may occur in the setting of elevated factor VIII activity above the upper limit of normal (ULN). Factor VIII activity above ULN has been reported following ROCTAVIAN infusion. Evaluate for risk factors for thrombosis including cardiovascular risk factors prior to and after ROCTAVIAN use and advise patients accordingly. ( 5.3 ) Monitoring laboratory tests: Monitor for factor VIII activity and factor VIII inhibitors. ( 5.4 ) Malignancy: Monitor for hepatocellular malignancy in patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age). Perform regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing following administration. In the event that any malignancy occurs after treatment with ROCTAVIAN, contact BioMarin Pharmaceutical Inc. at 1-866-906-6100. ( 5.5 ) 5.1 Infusion-Related Reactions Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during and/or following ROCTAVIAN administration . Symptoms included one or more of the following: urticaria, pruritus, rash, sneezing, coughing, dyspnea, rhinorrhea, watery eyes, tingling throat, nausea, diarrhea, hypotension, tachycardia, presyncope, pyrexia, rigors, and chills. Monitor patients during and for at least 3 hours after completion of ROCTAVIAN infusion. Do not infuse the product faster than 4 mL/min [see Dosage and Administration (2.3) ] . In the event of an infusion reaction, administration of ROCTAVIAN should be slowed or stopped. Restart at a lower rate after the infusion reaction has resolved. Discontinue infusion for anaphylaxis. Consider treatment with a corticosteroid, antihistamine, and other measures for management of an infusion reaction [see Dosage and Administration (2.3) ] . 5.2 Hepatotoxicity Intravenous administration of a liver-directed AAV vector could lead to liver enzyme elevations (transaminitis), especially ALT elevation. Transaminitis is presumed to occur due to immune-mediated injury of transduced hepatocytes and may reduce the therapeutic efficacy of AAV-vector based gene therapy. Majority of patients treated with ROCTAVIAN experienced ALT elevations. Most ALT elevations occurred within the first year following ROCTAVIAN administration, especially within the first 26 weeks, were low-grade, and resolved. The median time (range) to the first ALT elevation (defined as ALT ≥ 1.5 × baseline or above ULN) was 7 weeks (0.4, 159 weeks) and the median duration (range) was 4 weeks (0.1, 135 weeks). Some ALT elevations were associated with a decline in factor VIII activity. The majority of the 112 patients in the clinical trial of ROCTAVIAN required corticosteroids for ALT elevation [see Adverse Reactions (6.1) and Clinical Studies (14) ] . The median duration (range) of corticosteroid use was 35 weeks (3, 120 weeks). The median duration (range) of alternate immunosuppressive medications use was 26 weeks (6, 118 weeks). In 20 (18%) patients the duration of immunosuppression was > 1 year. Monitor ALT and institute corticosteroid treatment in response to ALT elevations, as required . Monitor ALT and factor VIII activity levels weekly and, as clinically indicated, during corticosteroid therapy [see Dosage and Administration (2.3) ] . Monitor for and manage adverse reactions secondary to corticosteroid therapy . Since some ALT elevations have been attributed to alcohol consumption in clinical studies, patients should abstain from alcohol consumption for at least a year following ROCTAVIAN infusion and limit alcohol use thereafter. Concomitant medications may cause hepatotoxicity, or decrease factor VIII activity, or change plasma corticosteroid levels which may impact liver enzyme elevation and/or factor VIII activity [see Drug Interactions (7.0 , 7.1 , 7.2) ] . Closely monitor concomitant medication use including herbal products and nutritional supplements and consider alternative medications in case of potential drug interactions. 5.3 Thromboembolic Events Elevated factor VIII activity level above the ULN as measured by the chromogenic substrate assays (CSA), or one-stage clotting assays (OSA), or both assays has occurred following ROCTAVIAN administration. Thirty-eight (28%) patients experienced elevations of factor VIII above ULN with a median time to first occurrence of 14 weeks and a median total duration above ULN of 12 weeks. An increase in factor VIII activity may increase the risk for venous and arterial thromboembolic events. There are no data in patients with a history of venous or arterial thromboembolism or known history of thrombophilia since such patients were excluded from clinical trials of ROCTAVIAN. Evaluate patients for risk of thrombosis including general cardiovascular risk factors before and after administration of ROCTAVIAN. Advise patients on their individual risk of thrombosis in relation to their factor VIII activity levels above ULN and consider prophylactic anticoagulation. Advise patients to seek immediate medical attention for signs or symptoms indicative of a thrombotic event. 5.4 Monitoring Laboratory Tests Factor VIII Assays Factor VIII activity produced by ROCTAVIAN in human plasma is higher if measured with OSA compared to CSA. In clinical studies, there was a high correlation between OSA and CSA factor VIII activity levels across the entire range of each assay's results [doi: 10.1182/blood.2020005683]. For routine clinical monitoring of factor VIII activity levels, either assay may be used. The conversion factor between the assays can be approximated based on clinical study results (central laboratory) to be: OSA = 1.5 × CSA. For example, a factor VIII activity level of 50 IU/dL using CSA calculates to a level of 75 IU/dL using OSA. The OSA to CSA ratio depends on the factor VIII assay reagents used by the laboratory and can range from 1.3 to 2.0, therefore, the same type of OSA or CSA reagents should be used to monitor factor VIII levels over time. When switching from hemostatic products prior to ROCTAVIAN treatment, physicians should refer to the relevant prescribing information to avoid the potential for factor VIII activity assay interference during the transition period. Factor VIII Inhibitors Monitor patients through appropriate clinical observations and laboratory tests for the development of factor VIII inhibitors after ROCTAVIAN administration. Perform an assay that detects factor VIII inhibitors if bleeding is not controlled, or plasma factor VIII activity levels decrease [see Dosage and Administration (2.3) ] . 5.5 Malignancy The integration of liver-targeting AAV vector DNA into the genome may carry the theoretical risk of hepatocellular carcinoma development. ROCTAVIAN is composed of a non-replicating AAV5 vector whose DNA persists largely in episomal form. Low levels of vector integration were found following evaluation of liver samples from 5 patients and parotid gland tissue sample from 1 patient in clinical studies and liver samples from 12 nonhuman primates [see Clinical Pharmacology (12.2) and Nonclinical Toxicology (13.1) ] . ROCTAVIAN can also insert into the DNA of other human body cells. No malignancies assessed as being likely related to ROCTAVIAN were observed in clinical studies. Monitor patients with risk factors for hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) with regular liver ultrasound (e.g., annually) and alpha-fetoprotein testing for 5 years following ROCTAVIAN administration [see Dosage and Administration (2.3) ] . In the event that a malignancy occurs, contact BioMarin Pharmaceutical Inc. at 1-866-906-6100 to obtain instructions on collecting patient samples for testing."],"clinical_studies_table":["
Table 9: Summary of ABRs and Bleeding Events (Rollover Population, N = 112)
ABR and Bleeding EventsBaselinePost-ROCTAVIAN Efficacy Evaluation Period
Min: Minimum; Max: Maximum; SD: Standard Deviation
Median (range) follow-up duration in years0.6 (0.5, 1.3)3.0 (1.7, 3.7)
Follow-up duration in person-years78.3342.8
Mean (SD) ABR in bleeds/year5.4 (6.9)2.6 (6.2)A total of 13 patients (12%) had used factor VIII replacement products or emicizumab during the efficacy evaluation period for prophylaxis, with a median start time at 2.3 (range: 0.1 to 3.3) years. An ABR of 35 was imputed for the periods when these patients were on prophylaxis.
Median (min, max) ABR in bleeds/year3.3 (0, 34.6)0.3 (0, 35.0)
Observed spontaneous bleed count (proportion of total bleeds)176 (42%)179 (41%)
Observed joint bleed count (proportion of total bleeds)240 (57%)195 (45%)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No animal studies have been conducted to evaluate the effects of ROCTAVIAN on carcinogenesis. To evaluate vector integration, host genomic DNA was isolated from liver tissues obtained from nonhuman primates at 13 and 26 weeks following intravenous administration of ROCTAVIAN at dose levels of up to 5.4 × 10 13 vg/kg. Vector DNA was mostly detected in the form of episomal DNA that was not integrated into the host genome. Vector integration events were observed at low frequencies and distributed throughout the host genome with no indication of clonal enrichment or preference to particular chromosomal locations, including genes associated with oncogenesis in humans [see Warnings and Precautions (5.5) and Clinical Pharmacology (12.2) ] . Since ROCTAVIAN vector DNA was detected in testes of adult male mice for at least 6 months following a single intravenous administration at dose level of 2.1 × 10 14 vg/kg [see Clinical Pharmacology (12.3) ] , the potential for vertical transmission to offspring was studied in Rag2-/- immunodeficient mice. A single intravenous administration of ROCTAVIAN at a dose level of 6.7 × 10 13 vg/kg into male immunodeficient mice that were mated 37 days later with naïve female mice did not result in adverse effects on fertility rates, pregnancy rates, and litter sizes. Quantitative polymerase chain reaction (qPCR) evaluation of liver tissues from the F1 pups did not detect the vector DNA. 13.2 Animal Toxicology and/or Pharmacology A single intravenous administration of up to 2.1 × 10 14 vg/kg of ROCTAVIAN in immunocompetent male mice with intact coagulation (CD1 mice), followed by an observation period of up to 26 weeks, showed dose-dependent toxicities in the heart, lung, thymus, and epididymis. At dose levels of 6.5 × 10 13 vg/kg and higher, histopathologic findings in the heart included minimal to moderate epicardial hemorrhage, myocardial necrosis, fibrosis, inflammation, and vascular/perivascular necrosis, minimal to mild mesothelial hypertrophy/hyperplasia, fibroplasia, myocardial atrophy, and vascular/perivascular mixed cell infiltrates. Lung findings included moderate to marked hemorrhage, minimal to mild edema, vascular/perivascular necrosis, and mesothelial hypertrophy. Additional ROCTAVIAN-related findings included mild fibrosis, hemorrhage, and pigmented macrophages in the epididymis, and moderate to marked hemorrhage and hypocellularity of the thymus. ROCTAVIAN-related mortality, adverse clinical observations, and changes in gross pathology were observed at dose levels of 6.5 × 10 13 vg/kg and higher, and were associated with fibrosis, hemorrhage, and necrosis in the heart. In a toxicology study conducted in adult male nonhuman primates with a duration of 3 months, single intravenous administration of ROCTAVIAN at dose levels of 1.6 × 10 13 vg/kg and 5.4 × 10 13 vg/kg resulted in a dose-dependent prolongation of activated partial thromboplastin time (APTT). The transient APTT prolongation in a subset of nonhuman primates was temporally associated with an immune response to hFVIII-SQ protein. At 3 months post-administration, histopathology findings included minimal to mild mononuclear/mixed infiltration in the lungs."],"pharmacodynamics_table":["
Table 7: Factor VIII Activity Levels (IU/dL) Over Time
TimepointRollover Population N = 112Directly Enrolled Population N = 22
CSA OSA CSA OSA
Month 3N = 111N = 111N = 22N = 22
Mean (SD)34.9 (40.4)54.6 (60.8)31.4 (25.7)48.3 (36.0)
Median (Q1, Q3)20.7 (10.3, 40.5)31.3 (15.3, 71.7)20.9 (12.6, 45.7)36.0 (22.4, 63.9)
Min, Max0, 249.51.5, 335.80, 85.84.5, 126.0
Month 6N = 111N = 111N = 22N = 22
Mean (SD)55.4 (57.5)84.9 (83.1)40.0 (37.9)63.0 (57.2)
Median (Q1, Q3)38.8 (16.8, 76.5)62.0 (28.0, 115.2)33.2 (14.7, 46.3)53.5 (23.7, 78.2)
Min, Max0, 367.31.9, 483.90, 169.41.8, 261.9
Month 10N = 111N = 111N = 20N = 20
Mean (SD)49.4 (49.5)73.6 (70.5)44.2 (49.6)70.2 (70.9)
Median (Q1, Q3)31.7 (17.1, 64.5)51.3 (25.1, 96.2)30.9 (14.1, 68.6)55.4 (24.8, 101.4)
Min, Max0, 265.31.2, 375.60, 223.62.4, 313.7
Month 12N = 111N = 111N = 21N = 21
Mean (SD)43.6 (45.5)64.7 (64.6)38.2 (46.3)59.7 (67.0)
Median (Q1, Q3)24.0 (12.5, 63.7)40.0 (20.4, 87.5)23.9 (11.2, 52.8)40.5 (17.4, 82.6)
Min, Max0, 231.20, 311.11.6, 207.44.4, 294.1
Month 18N = 99N = 99N = 18N = 18
Mean (SD)27.7 (32.3)40.6 (45.9)28.5 (28.9)44.5 (43.9)
Median (Q1, Q3)13.5 (6.9, 36.8)22.5 (10.9, 55.30)15.3 (10.8, 43.9)24.4 (17.7, 60.4)
Min, Max0, 167.90, 232.23.3, 117.04.2, 173.7
Month 24N = 98N = 99N = 19N = 18
Mean (SD)25.0 (35.5)38.9 (50.7)22.0 (28.7)36.0 (40.8)
Median (Q1, Q3)12.7 (5.1, 26.5)22.7 (7.9, 45.7)8.9 (5.8, 25.9)19.5 (7.9, 37.7)
Min, Max0, 187.10, 271.30, 110.62.4, 146.7
Month 36N = 96N = 97N = 15N = 15
Mean (SD)21.0 (34.0)33.8 (47.6)20.8 (24.4)32.2 (33.1)
Median (Q1, Q3)10.0 (4.3, 19.8)17.7 (7.2, 35.1)9.4 (6.6, 31.7)20.6 (8.5, 46.7)
Min, Max0, 217.70, 291.40, 74.51.9, 104.2
","
Table 8: Patients Achieving Factor VIII Activity Thresholds by Year
Rollover Population (N = 112)
Factor VIII Activity Threshold Achieved by AssayYear 1 N = 111 n (%)Year 2 N = 98 n (%)Year 3 N = 96 n (%)
CSA
> 150 IU/dL6 (5%)2 (2%)2 (2%)
40 - ≤ 150 IU/dL37 (33%)14 (14%)9 (9%)
15 - < 40 IU/dL37 (33%)27 (28%)23 (24%)
5 - < 15 IU/dL18 (16%)33 (34%)35 (36%)
3 - < 5 IU/dL3 (3%)10 (10%)8 (8%)
< 3 IU/dL10 (9%)12 (12%)19 (20%)
Year 1 N = 111 n (%)Year 2 N = 99 n (%)Year 3 N = 97 n (%)
OSA
> 150 IU/dL12 (11%)5 (5%)4 (4%)
40 - ≤ 150 IU/dL44 (40%)25 (25%)17 (18%)
15 - < 40 IU/dL37 (33%)36 (36%)36 (37%)
5 - < 15 IU/dL10 (9%)20 (20%)26 (27%)
1 - < 5 IU/dL6 (5%)11 (11%)12 (12%)
< 1 IU/dL2 (2%)2 (2%)2 (2%)
Directly Enrolled Population (N = 22)
Factor VIII Activity Threshold Achieved by AssayYear 1 N = 21 n (%)Year 2 N = 19 n (%)Year 3 N = 15 n (%)
CSA
> 150 IU/dL1 (5%)0 (0%)0 (0%)
40 - ≤ 150 IU/dL5 (24%)3 (16%)3 (20%)
15 - < 40 IU/dL8 (38%)4 (21%)2 (13%)
5 - < 15 IU/dL5 (24%)8 (42%)7 (47%)
3 - < 5 IU/dL0 (0%)1 (5%)1 (7%)
< 3 IU/dL2 (10%)3 (16%)2 (13%)
Year 1 N = 21 n (%)Year 2 N = 18 n (%)Year 3 N = 15 n (%)
OSA
> 150 IU/dL1 (5%)0 (0%)0 (0%)
40 - ≤ 150 IU/dL10 (48%)4 (22%)4 (27%)
15 - < 40 IU/dL6 (29%)6 (33%)6 (40%)
5 - < 15 IU/dL3 (14%)6 (33%)3 (20%)
1 - < 5 IU/dL1 (5%)2 (11%)2 (13%)
< 1 IU/dL0 (0%)0 (0%)0 (0%)
"],"adverse_reactions_table":["
Table 5: Adverse Reactions in ≥ 5%Other adverse reactions include gastroenteritis (2 patients; 1%), rash (2 patients; 1%), diarrhea (6 patients; 4%), and dizziness (3 patients; 2%). of Patients Treated with ROCTAVIAN
Adverse ReactionsNumber of Patients (%) N = 134
All Grades≥ Grade 3
Nervous system disorders
Headache9 (7%)0 (0%)
Gastrointestinal disorders
Nausea42 (31%)0 (0%)
Vomiting8 (6%)0 (0%)
Abdominal painIncludes abdominal discomfort, abdominal distension, abdominal tenderness, and abdominal pain upper.8 (6%)0 (0%)
General disorders and administration site conditions
FatigueIncludes fatigue, lethargy, and malaise.21 (16%)0 (0%)
Infusion-related reactionsInfusion-related reactions are not under a specific system organ class and include multiple symptoms that occurred during or within 6 hours after the end of infusion [see Warnings and Precautions (5.1)].9 (7%)2 (1%)
","
Table 6: Laboratory Abnormalities in Patients Treated with ROCTAVIAN
Laboratory AbnormalitiesNumber of Patients (%) N = 134
ALT increases > ULN109 (81%)
AST increases > ULN92 (69%)
LDH increases > ULN77 (57%)
CPK increases > ULN60 (45%)
Factor VIII activity levels > ULNPatients with one or more instances of factor VIII activity levels > 170 IU/dL (ULN of the CSA used) or > 150 IU/dL (ULN of the OSA used) [see Warnings and Precautions (5.3)].38 (28%)
GGT increases > ULN24 (18%)
Bilirubin increases > ULN18 (13%)
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Inform patients of the following risks and required precautions prior to ROCTAVIAN infusion: Pre-Infusion Assessments Inform patients that prior to dosing ROCTAVIAN the following will be necessary: Blood tests to look for factor VIII inhibitors and detect antibodies to AAV5. If these tests are positive, the patient will not be a candidate for ROCTAVIAN [see Dosage and Administration (2) and Use in Special Populations (12.6) ] . Liver health assessments, which include measuring liver function tests, liver ultrasound, and elastography or laboratory assessments for assessing hepatic fibrosis. If these tests are abnormal, the patient may not be a good candidate for ROCTAVIAN [see Dosage and Administration (2) ] . Assessment for suitability for corticosteroids and/or other immunosuppressive therapy. Inform patients that they may receive corticosteroids and/or other immunosuppressive agents for an extended period of time and communicate any risks associated with these therapies. The baseline assessment for suitability for immunosuppression may deem that the patient is not a good candidate for immunosuppression and hence not a good candidate for ROCTAVIAN [see Dosage and Administration (2 , 2.3) ] . Adverse Reactions During and After Infusion Inform patients that infusion reactions including anaphylaxis have occurred. Patients will be monitored during and for at least 3 hours after infusion [see Warnings and Precautions (5.1) ] . Educate patients on possible symptoms of infusion reactions during and after infusion and advise them to immediately inform medical staff if they experience such a reaction [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . When discharging the patient, provide instructions on actions in case of a new or recurrent reaction and when to seek medical attention. Importance of Liver Enzyme and Factor VIII Level Monitoring ROCTAVIAN can cause elevation of certain liver enzymes. Elevation in liver enzymes may be associated with decrease in factor VIII activity [see Warnings and Precautions (5.2) ] . Weekly blood test will be required for at least 26 weeks for monitoring this. Monitoring beyond this time is usually less frequent but depends on clinical situation, prior laboratory test results, and ongoing treatment with corticosteroids or other immunosuppressive therapy. [see Dosage and Administration (2.3) ] . Use of Factor VIII Concentrates/Hemostatic Agents after Treatment with ROCTAVIAN Advise patients on tapering factor VIII concentrates/hemostatic agents and, as necessary, on whether and how to continue or re-start their use, and on actions in case of invasive procedures, surgery, trauma, or bleeds [see Dosage and Administration (2.3) ] . Advise patients that not all patients may respond to ROCTAVIAN and that currently it is not possible to predict who will respond and how long the treatment response will continue. Counsel patients, as necessary, on when they may need to re-instate prophylactic use of factor VIII concentrates/hemostatic agents [see Dosage and Administration (2.3) ] . Corticosteroid Regimen and Alternate Immunosuppression Inform patients undergoing corticosteroid treatment to adhere to the regimen and about potential adverse reactions and necessary precautions [see Dosage and Administration (2.3) and Warnings and Precautions (5.2) ] . Advise patients that treatment with immunosuppressive agents other than corticosteroids may be required in case of intolerance, or adverse event from or failure of corticosteroid therapy [see Dosage and Administration (2.3) ] . Hepatic Health Advise patients on how to maintain or improve hepatic health. Advise patients that they should abstain from consuming alcohol for at least one year after treatment and how much alcohol may be acceptable for them in the longer term [see Warnings and Precautions (5.2) ] . Advise patients not to use any medications, herbal products, or supplements without first confirming with a health professional that they are not hepatotoxic. Instruct patients that they or their healthcare professional contact you if use of a hepatotoxic agent appears unavoidable, to discuss potential alternatives and any implications for patient monitoring i.e., more frequent monitoring of liver enzymes and factor VIII activity may be needed [see Warnings and Precautions (5.2) and Drug Interactions (7) ] . Thromboembolic Events Inform patients that elevated factor VIII activity above the upper limit of normal has occurred following ROCTAVIAN administration. Elevated factor VIII activity above the upper limit of normal may increase the risk of a thromboembolic event [see Warnings and Precautions (5.3) ] . As necessary, advise patients of their risk factors for thrombotic events and general cardiovascular risk factors, how to minimize their risk, how to recognize a thrombotic event and to seek immediate medical attention if they observe signs or symptoms that can indicate a thrombotic event [see Warnings and Precautions (5.3) ] . Contraception and Semen Donation Advise patients that, after a male patient has been treated with ROCTAVIAN, the patient and/or his female partner must avoid pregnancy for a period of 6 months, and that male patients must not donate semen for a period of 6 months [see Use in Specific Populations (8.3) ] . Instruct patients on acceptable methods of contraception. Blood, Organ, Tissue and Cell Donation Advise patients not to donate blood, organs, tissues, and cells for transplantation after treatment with ROCTAVIAN. Repeat Treatment and Impact on Receiving Other AAV Gene Therapies Advise patients that ROCTAVIAN is a one-time treatment. Currently, treatment with ROCTAVIAN precludes the patient from receiving another gene therapy for hemophilia. Malignancy Inform patients that since ROCTAVIAN is a liver-directed AAV therapy, there may be a theoretical risk of hepatocellular carcinoma. Patients with risk factors for hepatocellular carcinoma should be monitored regularly for 5 years with regular ultrasound and blood tests (alpha-fetoprotein). No malignancies assessed as being likely related to ROCTAVIAN treatment have been reported in clinical trials. Since the vector can insert into DNA of any cell, other malignancies may also occur [see Warnings and Precautions (5.5) ] . Advise patients to contact BioMarin Pharmaceutical Inc. (1-866-906-6100) if they are diagnosed with any malignancy [see Warnings and Precautions (5.5) ] . Long-Term Follow-Up Inform patients that they should be enrolled in a 15-year registry to evaluate the long-term efficacy and safety of hemophilia treatments."],"spl_unclassified_section":["Manufactured by: BioMarin Pharmaceutical Inc. Novato, CA 94949 US License Number 1649"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For one-time single-dose intravenous use only. Treatment with ROCTAVIAN should be under the supervision of a physician experienced in the treatment of hemophilia and/or bleeding disorders. For one-time single-dose intravenous use only. ( 2 ) Perform baseline testing to select patients, including testing for pre-existing antibodies to adeno-associated virus serotype 5 (AAV5), factor VIII inhibitor presence, and liver health assessments. ( 2 ) The recommended dose of ROCTAVIAN is 6 × 10 13 vector genomes (vg) per kg of body weight. ( 2.1 ) Start the infusion at 1 mL/min. If tolerated, the rate may be increased every 30 minutes by 1 mL/min up to a maximum rate of 4 mL/min. ( 2.1 ) For Patient Selection Perform testing for pre-existing antibodies to AAV5 using the FDA approved companion diagnostic. DO NOT administer ROCTAVIAN to patients with a positive test for antibodies to AAV5. Information on FDA-approved tests for the detection of antibodies to AAV5 is available at: http://www.fda.gov/CompanionDiagnostics . Perform factor VIII inhibitor titer testing [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.6) ] . DO NOT administer ROCTAVIAN to a patient with a positive test for factor VIII inhibitor. Perform liver health assessments, which include: Liver function tests [alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), total bilirubin and international normalized ration (INR)] Ultrasound and elastography or laboratory assessments for liver fibrosis In case of radiological liver abnormalities and/or liver function test abnormalities (ALT, AST, GGT, ALP or total bilirubin > 1.25 × ULN or INR ≥ 1.4), consider a consultation with a hepatologist to assess eligibility for ROCTAVIAN. Assess patient's ability to receive corticosteroids and/or other immunosuppressive therapy that may be required for an extended period [see Dosage and Administration (2.3) ] . Ensure that the risks associated with immunosuppression are acceptable for the individual patient. DO NOT administer ROCTAVIAN to patients with active acute or uncontrolled chronic infections, known significant hepatic fibrosis (stage 3 or 4 on the Batts-Ludwig scale or equivalent) or cirrhosis, or mannitol hypersensitivity [see Contraindications (4) and Use in Specific Populations (8.8) ] . 2.1 Dose The recommended dose of ROCTAVIAN is 6 × 10 13 vector genomes per kilogram (vg/kg) body weight, administered as a single intravenous infusion. ROCTAVIAN is administered using an infusion pump at a rate of 1 mL/min, which can be increased every 30 minutes by 1 mL/min up to a maximum rate of 4 mL/min. Calculating Dose in Milliliters (mL) and Number of Vials Required Patient dose volume in mL: Body weight in kg multiplied by 3 = dose in mL. The multiplication factor 3 represents the per kilogram dose (6 × 10 13 vg/kg) divided by the amount of vector genomes per mL of the ROCTAVIAN suspension (2 × 10 13 vg/mL). Number of ROCTAVIAN vials to be thawed: Patient dose volume (mL) divided by 8 = number of vials to be thawed (round up to next whole number of vials). The division factor 8 represents the minimum volume of ROCTAVIAN extractable from a vial (8 mL). Table 1: Example of Dose Volume and Number of Vials to be Thawed Patient Weight Patient Dose by Volume (mL) (body weight multiplied by 3) Number of Vials to be Thawed (dose volume divided by 8, then rounded up) 70 kg 210 mL 27 vials (rounded up from 26.25) ROCTAVIAN can be administered only once. 2.2 Preparation for Administration Required Equipment and Materials Flow rate-controlled syringe pump Syringes for ROCTAVIAN administration (the number of syringes will depend on the patient's dose volume and the syringe pump used and should be prepared prior to administration of ROCTAVIAN) 18- to 21-gauge sharp needles High-volume, in-line, low protein binding infusion filter with a pore size of 0.22 microns and maximum operating pressure adequate for the syringe pump or pump settings. Ensure availability of a sufficient number of replacement filters, according to the specifications for maximum filtered fluid volume. Syringe of 0.9% Sodium Chloride Injection, USP sodium chloride 9 mg/mL (0.9%) solution for priming and flushing the infusion line When assembling the infusion system, refer to the compatible materials with ROCTAVIAN suspension listed in Table 2. Table 2: Compatible Infusion System Component Materials Component Compatible Materials Syringes Polypropylene barrel with a synthetic rubber plunger tip Syringe cap Polypropylene Infusion tubing Tubing extensions should not exceed 40 inches in length. Polyethylene 0.22 micron in-line filter Polyvinylidene fluoride filter with polyvinyl chloride body Infusion catheter Polyurethane based polymer Stopcocks Polycarbonate 18 to 21-gauge sharp needles for extraction from vials Do not use filter needles to extract ROCTAVIAN from vials. Stainless steel General Precautions Do not expose ROCTAVIAN to the light of an ultraviolet radiation disinfection lamp. Prepare ROCTAVIAN using aseptic technique. Wear gloves and safety glasses during preparation and administration. Treat spills of ROCTAVIAN with a virucidal agent with proven activity against non-enveloped viruses and blot using absorbent materials. Dispose unused medicinal product and materials that may have come in contact with ROCTAVIAN in accordance with the local biosafety guidelines. Thaw and Inspect 1. Keep each vial in its carton until ready to thaw. ROCTAVIAN is sensitive to light. 2. Thaw ROCTAVIAN at room temperature. Do not thaw or warm vials any other way. Thawing time is approximately 2 hours. 3. Remove the required number of vials from their cartons. 4. Inspect the vials for damage to the vial or cap. Do not use if damaged. 5. Set the vials upright. To achieve optimal thawing, spread them out evenly or place them in racks that have been kept at room temperature. 6. Visually confirm that all vials have been thawed. There should be no visible ice. 7. Very gently invert each vial 5 times to mix. It is important to minimize foaming. 8. Let the suspension settle for approximately 5 minutes before continuing. 9. Visually inspect the fully thawed vials. Do not use a vial if the suspension is not clear, not colorless to pale yellow, or contains visible particles. ROCTAVIAN contains no preservative. For microbiological safety, keep the thawed suspension in the vials until it is time for infusion. If necessary, an intact vial (stopper not yet punctured) that has been thawed at room temperature can be stored refrigerated between 2 to 8°C (36 to 46°F) for up to 3 days, upright and protected from light (e.g., in the original carton). Thawed ROCTAVIAN (in vials or syringes) can be held at room temperature, up to 25°C (77°F), for a maximum of 10 hours including hold time in intact vial, preparation time into the syringes, and duration of infusion. Extraction into Syringes 10. Using 18 to 21-gauge sharp needles, slowly extract ROCTAVIAN from the vials into the infusion-pump syringes. All infusion-pump syringes should be prepared prior to administering ROCTAVIAN. The contents of multiple vials may be combined into a single syringe. Addition of In-line Filter and Priming of the Infusion System 11. Insert the in-line filter close to the infusion site. 12. Prime tubing and filter with ROCTAVIAN. 13. When replacing filters during the infusion, use 0.9% Sodium Chloride Injection, USP, for priming and flushing. Incompatibilities Do not use infusion system components other than those described in Table 2. ROCTAVIAN must not be mixed or diluted with infusion solutions; 0.9% Sodium Chloride Injection, USP is used to prime and flush the infusion line. 2.3 Administration Administer ROCTAVIAN in a setting where personnel and equipment are immediately available to treat infusion-related reactions [see Warnings and Precautions (5.1) ] . Infuse the suspension through a suitable peripheral vein, using an infusion catheter with in-line filter and a programmable syringe pump. Start the infusion at a rate of 1 mL/min. If tolerated, the rate may be increased every 30 minutes by 1 mL/min up to a maximum rate of 4 mL/min. The infusion time depends on infusion volume, rate and patient response and can be, for example, 2 to 5 hours or longer for a patient weighing 100 kg. In the event of an infusion-related reaction during administration [see Warnings and Precautions (5.1) ] , Decrease the infusion rate or stop the infusion. Administer treatment as needed to manage infusion reaction. If the infusion is stopped, restart the infusion at a rate of 1 mL/min and consider maintaining it at a previously tolerated level for the remainder of the infusion. If the infusion needs to be restarted, the infusion should be completed within 10 hours of initial drug product thaw. Discontinue infusion for anaphylaxis. DO NOT administer ROCTAVIAN as an intravenous push or bolus. DO NOT infuse ROCTAVIAN in the same intravenous line with any other products. DO NOT use a central line or port. To ensure the patient receives the complete dose, after the content of the last ROCTAVIAN-containing syringe is infused, flush the infusion line with a sufficient volume of 0.9% Sodium Chloride Injection, USP, through the same tubing and filter, and at the same infusion rate. Maintain venous access during the subsequent observation period [see Warnings and Precautions (5.1) ] . Monitoring Post-Administration Conduct the following tests after ROCTAVIAN administration [see Warnings and Precautions (5.2 , 5.4 , 5.5) ] . Perform regular ALT testing to monitor for elevations. Elevated liver enzymes, especially elevated ALT, may indicate immune-mediated hepatotoxicity and may be associated with decline in factor VIII activity. The monitoring schedule for ALT, and recommendations for corticosteroid use (initiation and taper) are based on the clinical efficacy and safety experience of 112 patients in a clinical study with ROCTAVIAN. Monitor ALT weekly for at least 26 weeks following administration of ROCTAVIAN. See Table 3 for monitoring schedule. Monitor AST and creatine phosphokinase (CPK) as needed to help rule out alternative causes for ALT elevations (including potentially hepatotoxic medications or agents, alcohol consumption, or strenuous exercise). Consider repeating ALT testing within 24 to 48 hours to confirm ALT elevation prior to initiation of corticosteroid treatment and using the same laboratory to measure ALT activity at baseline and over time to minimize the impact of inter-laboratory variability on test results. If ALT ≥ 1.5 × baseline or above ULN consider corticosteroid treatment. For patients who need corticosteroid therapy, the recommended starting dose is 60 mg with a subsequent taper upon return of ALT levels to baseline (see Table 4 below for recommendation on corticosteroid treatment). Monitor ALT weekly, and as clinically indicated, during corticosteroid therapy. Continue to monitor ALT until its return to baseline. Monitor for and manage adverse reactions secondary to corticosteroid use. Refer to the corticosteroid prescribing information for risks and required precautions. Table 3: ALT Monitoring Post-Administration Monitoring of ALT may be accompanied by monitoring of AST and CPK to rule out other causes of ALT elevation. Timeframe Monitoring Frequency Weekly monitoring is recommended, and as clinically indicated, during corticosteroid tapering. First 26 weeks Weekly Weeks 26 to 52 (Year 1) Every 1 to 2 weeks Year 2 Every 3 months After Year 2 Every 6 months Table 4: Recommended Corticosteroid Regimen in Response to ALT Elevations Corticosteroid Regimen (Prednisone or Equivalent Dose of Another Corticosteroid) Starting Dose If ALT continues to rise or has not improved after 2 weeks, increase the corticosteroid dose up to a maximum of 1.2 mg/kg, after ruling out alternative causes for ALT elevation. 60 mg daily for 2 weeks Tapering Taper corticosteroids after ALT levels reach baseline. The taper may be individualized based on the trend of ALT decline, the patient's medical condition, corticosteroid tolerance, and adverse reactions to corticosteroid therapy. 40 mg daily for 3 weeks 30 mg daily for 1 week 20 mg daily for 1 week 10 mg daily for 1 week There is limited information on the benefit of starting a corticosteroid course after the first year of ROCTAVIAN administration. Other immunosuppressive therapies (e.g., tacrolimus, mycophenolate mofetil) may be considered if corticosteroids are contraindicated, ineffective or there are adverse reactions secondary to corticosteroid use necessitating discontinuation. Monitor Factor VIII Activity Monitor factor VIII activity using the same schedule for ALT monitoring in Table 3 [see Warnings and Precautions (5.4) ] . Consider more frequent monitoring in patients with factor VIII activity levels ≤ 5 IU/dL and evidence of bleeding, taking into account the stability of factor VIII levels since the previous measurement. It may take several weeks after ROCTAVIAN infusion before ROCTAVIAN-derived factor VIII activity rises to a level sufficient for prevention of spontaneous bleeding episodes. Therefore, continued routine prophylaxis support with exogenous factor VIII or other hemostatic products used in the management of hemophilia A may be needed during the first few weeks after ROCTAVIAN infusion [see Clinical Pharmacology (12.3) ] . Exogenous factor VIII or other hemostatic products may also be required in case of surgery, invasive procedures, trauma, or bleeds in the event that ROCTAVIAN-derived factor VIII activity is deemed insufficient for adequate hemostasis in such situations. The use of different assays may impact test results; therefore, use the same assay and reagents to monitor patients over time, if feasible [see Warnings and Precautions (5.4) ] . Use of exogenous factor VIII products before and after ROCTAVIAN administration may impede assessment of ROCTAVIAN-derived factor VIII activity. Monitor patients for factor VIII inhibitors (neutralizing antibodies to factor VIII). Test for factor VIII inhibitors especially if bleeding is not controlled, or plasma factor VIII activity levels decrease [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.6) ] . Perform regular liver ultrasound (e.g., annually) and alpha-fetoprotein (AFP) testing in patients with risk factors of hepatocellular carcinoma (e.g., hepatitis B or C, non-alcoholic fatty liver disease, chronic alcohol consumption, non-alcoholic steatohepatitis, advanced age) [see Warnings and Precautions (5.5) ] ."],"spl_product_data_elements":["ROCTAVIAN valoctocogene roxaparvovec-rvox VALOCTOCOGENE ROXAPARVOVEC VALOCTOCOGENE ROXAPARVOVEC"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS ROCTAVIAN is a clear, colorless to pale yellow suspension for intravenous infusion containing 2 × 10 13 vg valoctocogene roxaparvovec-rvox per mL. ROCTAVIAN is provided in vials containing an extractable volume of not less than 8 mL. Dose volume is based on body weight, with a recommended dose of 6 × 10 13 vg/kg. ROCTAVIAN is a suspension for intravenous infusion. ( 3 ) ROCTAVIAN has a nominal concentration of 2 × 10 13 vg valoctocogene roxaparvovec-rvox per mL, each vial contains an extractable volume of not less than 8 mL (16 × 10 13 vg). ( 3 )"],"clinical_pharmacology_table":["
Table 7: Factor VIII Activity Levels (IU/dL) Over Time
TimepointRollover Population N = 112Directly Enrolled Population N = 22
CSA OSA CSA OSA
Month 3N = 111N = 111N = 22N = 22
Mean (SD)34.9 (40.4)54.6 (60.8)31.4 (25.7)48.3 (36.0)
Median (Q1, Q3)20.7 (10.3, 40.5)31.3 (15.3, 71.7)20.9 (12.6, 45.7)36.0 (22.4, 63.9)
Min, Max0, 249.51.5, 335.80, 85.84.5, 126.0
Month 6N = 111N = 111N = 22N = 22
Mean (SD)55.4 (57.5)84.9 (83.1)40.0 (37.9)63.0 (57.2)
Median (Q1, Q3)38.8 (16.8, 76.5)62.0 (28.0, 115.2)33.2 (14.7, 46.3)53.5 (23.7, 78.2)
Min, Max0, 367.31.9, 483.90, 169.41.8, 261.9
Month 10N = 111N = 111N = 20N = 20
Mean (SD)49.4 (49.5)73.6 (70.5)44.2 (49.6)70.2 (70.9)
Median (Q1, Q3)31.7 (17.1, 64.5)51.3 (25.1, 96.2)30.9 (14.1, 68.6)55.4 (24.8, 101.4)
Min, Max0, 265.31.2, 375.60, 223.62.4, 313.7
Month 12N = 111N = 111N = 21N = 21
Mean (SD)43.6 (45.5)64.7 (64.6)38.2 (46.3)59.7 (67.0)
Median (Q1, Q3)24.0 (12.5, 63.7)40.0 (20.4, 87.5)23.9 (11.2, 52.8)40.5 (17.4, 82.6)
Min, Max0, 231.20, 311.11.6, 207.44.4, 294.1
Month 18N = 99N = 99N = 18N = 18
Mean (SD)27.7 (32.3)40.6 (45.9)28.5 (28.9)44.5 (43.9)
Median (Q1, Q3)13.5 (6.9, 36.8)22.5 (10.9, 55.30)15.3 (10.8, 43.9)24.4 (17.7, 60.4)
Min, Max0, 167.90, 232.23.3, 117.04.2, 173.7
Month 24N = 98N = 99N = 19N = 18
Mean (SD)25.0 (35.5)38.9 (50.7)22.0 (28.7)36.0 (40.8)
Median (Q1, Q3)12.7 (5.1, 26.5)22.7 (7.9, 45.7)8.9 (5.8, 25.9)19.5 (7.9, 37.7)
Min, Max0, 187.10, 271.30, 110.62.4, 146.7
Month 36N = 96N = 97N = 15N = 15
Mean (SD)21.0 (34.0)33.8 (47.6)20.8 (24.4)32.2 (33.1)
Median (Q1, Q3)10.0 (4.3, 19.8)17.7 (7.2, 35.1)9.4 (6.6, 31.7)20.6 (8.5, 46.7)
Min, Max0, 217.70, 291.40, 74.51.9, 104.2
","
Table 8: Patients Achieving Factor VIII Activity Thresholds by Year
Rollover Population (N = 112)
Factor VIII Activity Threshold Achieved by AssayYear 1 N = 111 n (%)Year 2 N = 98 n (%)Year 3 N = 96 n (%)
CSA
> 150 IU/dL6 (5%)2 (2%)2 (2%)
40 - ≤ 150 IU/dL37 (33%)14 (14%)9 (9%)
15 - < 40 IU/dL37 (33%)27 (28%)23 (24%)
5 - < 15 IU/dL18 (16%)33 (34%)35 (36%)
3 - < 5 IU/dL3 (3%)10 (10%)8 (8%)
< 3 IU/dL10 (9%)12 (12%)19 (20%)
Year 1 N = 111 n (%)Year 2 N = 99 n (%)Year 3 N = 97 n (%)
OSA
> 150 IU/dL12 (11%)5 (5%)4 (4%)
40 - ≤ 150 IU/dL44 (40%)25 (25%)17 (18%)
15 - < 40 IU/dL37 (33%)36 (36%)36 (37%)
5 - < 15 IU/dL10 (9%)20 (20%)26 (27%)
1 - < 5 IU/dL6 (5%)11 (11%)12 (12%)
< 1 IU/dL2 (2%)2 (2%)2 (2%)
Directly Enrolled Population (N = 22)
Factor VIII Activity Threshold Achieved by AssayYear 1 N = 21 n (%)Year 2 N = 19 n (%)Year 3 N = 15 n (%)
CSA
> 150 IU/dL1 (5%)0 (0%)0 (0%)
40 - ≤ 150 IU/dL5 (24%)3 (16%)3 (20%)
15 - < 40 IU/dL8 (38%)4 (21%)2 (13%)
5 - < 15 IU/dL5 (24%)8 (42%)7 (47%)
3 - < 5 IU/dL0 (0%)1 (5%)1 (7%)
< 3 IU/dL2 (10%)3 (16%)2 (13%)
Year 1 N = 21 n (%)Year 2 N = 18 n (%)Year 3 N = 15 n (%)
OSA
> 150 IU/dL1 (5%)0 (0%)0 (0%)
40 - ≤ 150 IU/dL10 (48%)4 (22%)4 (27%)
15 - < 40 IU/dL6 (29%)6 (33%)6 (40%)
5 - < 15 IU/dL3 (14%)6 (33%)3 (20%)
1 - < 5 IU/dL1 (5%)2 (11%)2 (13%)
< 1 IU/dL0 (0%)0 (0%)0 (0%)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS For 6 months after administration, men must not donate semen, and men and their female partners must prevent or postpone pregnancy. ( 8.3 ) There is limited information on the safety and effectiveness of ROCTAVIAN in patients with HIV infection. ( 8.6 ) The safety and effectiveness of ROCTAVIAN in patients with prior or active factor VIII inhibitors have not been established. ( 8.7 ) 8.1 Pregnancy Risk Summary ROCTAVIAN is not intended for administration in women. There are no data on the use of ROCTAVIAN in pregnant women to inform a drug-associated risk of adverse developmental outcome. Animal reproduction and developmental toxicity studies have not been conducted with ROCTAVIAN. It is not known whether ROCTAVIAN can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the US general population, the estimated background risk of major birth defects occurs in 2 to 4% of the general population and miscarriage occurs in 15 to 20% of clinically recognized pregnancies. 8.2 Lactation Risk Summary ROCTAVIAN is not intended for administration in women. There is no information regarding the presence of ROCTAVIAN in human milk, the effects on the breastfed infant, or the effects on milk production. 8.3 Females and Males of Reproductive Potential ROCTAVIAN is not intended for administration in women. Contraception After Administration to Males In clinical studies, after administration of ROCTAVIAN, transgene DNA was detectable in semen [see Clinical Pharmacology (12.3) ] . In nonclinical studies in healthy mice, the vector DNA was detected in the testes for at least 182 days post-administration of ROCTAVIAN at a dose level of 2.1 × 10 14 vg/kg [see Clinical Pharmacology (12.3) ]. In a mating study in immune-deficient mice, ROCTAVIAN was not detected in liver tissues of offspring of naïve females mated with dosed males [see Nonclinical Toxicology (13.1) ]. For 6 months after administration of ROCTAVIAN men of reproductive potential and their female partners must prevent or postpone pregnancy using an effective form of contraception, and men must not donate semen. 8.4 Pediatric Use The safety and effectiveness of ROCTAVIAN in pediatric patients have not been established. 8.5 Geriatric Use A single patient ≥ 65 years of age was treated with ROCATVIAN in clinical studies. Clinical studies of ROCTAVIAN did not include sufficient numbers of patients aged 65 and over to determine whether the efficacy or safety differs compared to younger patients. 8.6 Human Immunodeficiency Virus (HIV) Positive Patients In clinical studies, 3 HIV infected patients have been treated with ROCTAVIAN. Clinical studies of ROCTAVIAN did not include sufficient numbers of patients with HIV to determine whether the efficacy and safety differs compared to patients without HIV infection. A single HIV infected patient treated with ROCTAVIAN developed hepatocellular injury that subsequently resolved and was attributed to concomitant administration with antiretroviral drug efavirenz [see Drug Interactions (7.2) ] . 8.7 Factor VIII Inhibitors The safety and effectiveness of ROCTAVIAN in patients with prior or active factor VIII inhibitors have not been established [see Clinical Pharmacology (12.6) ] . Patients with active factor VIII inhibitors should not take ROCTAVIAN. After administration of ROCTAVIAN, patients should be monitored for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests [see Warnings and Precautions (5.4) ] . 8.8 Hepatic Impairment The safety and effectiveness of ROCTAVIAN in patients with hepatic impairment has not been established. Clinical studies excluded patients with known hepatic cirrhosis, significant fibrosis (stage 3 or 4 on the Batts-Ludwig scale or equivalent), current hepatitis B or C, or history of hepatic malignancy. No dose adjustments can be recommended for patients with hepatic impairment. 8.9 Renal Impairment The safety and effectiveness of ROCTAVIAN in patients with renal impairment has not been established. No dose adjustments can be recommended for patients with renal impairment."],"dosage_and_administration_table":["
Table 1: Example of Dose Volume and Number of Vials to be Thawed
Patient WeightPatient Dose by Volume (mL) (body weight multiplied by 3)Number of Vials to be Thawed (dose volume divided by 8, then rounded up)
70 kg210 mL27 vials (rounded up from 26.25)
","
Table 2: Compatible Infusion System Component Materials
ComponentCompatible Materials
SyringesPolypropylene barrel with a synthetic rubber plunger tip
Syringe capPolypropylene
Infusion tubingTubing extensions should not exceed 40 inches in length.Polyethylene
0.22 micron in-line filterPolyvinylidene fluoride filter with polyvinyl chloride body
Infusion catheterPolyurethane based polymer
StopcocksPolycarbonate
18 to 21-gauge sharp needles for extraction from vialsDo not use filter needles to extract ROCTAVIAN from vials.Stainless steel
","
Table 3: ALT Monitoring Post-AdministrationMonitoring of ALT may be accompanied by monitoring of AST and CPK to rule out other causes of ALT elevation.
TimeframeMonitoring FrequencyWeekly monitoring is recommended, and as clinically indicated, during corticosteroid tapering.
First 26 weeksWeekly
Weeks 26 to 52 (Year 1)Every 1 to 2 weeks
Year 2Every 3 months
After Year 2Every 6 months
","
Table 4: Recommended Corticosteroid Regimen in Response to ALT Elevations
Corticosteroid Regimen (Prednisone or Equivalent Dose of Another Corticosteroid)
Starting DoseIf ALT continues to rise or has not improved after 2 weeks, increase the corticosteroid dose up to a maximum of 1.2 mg/kg, after ruling out alternative causes for ALT elevation.60 mg daily for 2 weeks
TaperingTaper corticosteroids after ALT levels reach baseline. The taper may be individualized based on the trend of ALT decline, the patient's medical condition, corticosteroid tolerance, and adverse reactions to corticosteroid therapy.40 mg daily for 3 weeks 30 mg daily for 1 week 20 mg daily for 1 week 10 mg daily for 1 week
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology A single intravenous administration of up to 2.1 × 10 14 vg/kg of ROCTAVIAN in immunocompetent male mice with intact coagulation (CD1 mice), followed by an observation period of up to 26 weeks, showed dose-dependent toxicities in the heart, lung, thymus, and epididymis. At dose levels of 6.5 × 10 13 vg/kg and higher, histopathologic findings in the heart included minimal to moderate epicardial hemorrhage, myocardial necrosis, fibrosis, inflammation, and vascular/perivascular necrosis, minimal to mild mesothelial hypertrophy/hyperplasia, fibroplasia, myocardial atrophy, and vascular/perivascular mixed cell infiltrates. Lung findings included moderate to marked hemorrhage, minimal to mild edema, vascular/perivascular necrosis, and mesothelial hypertrophy. Additional ROCTAVIAN-related findings included mild fibrosis, hemorrhage, and pigmented macrophages in the epididymis, and moderate to marked hemorrhage and hypocellularity of the thymus. ROCTAVIAN-related mortality, adverse clinical observations, and changes in gross pathology were observed at dose levels of 6.5 × 10 13 vg/kg and higher, and were associated with fibrosis, hemorrhage, and necrosis in the heart. In a toxicology study conducted in adult male nonhuman primates with a duration of 3 months, single intravenous administration of ROCTAVIAN at dose levels of 1.6 × 10 13 vg/kg and 5.4 × 10 13 vg/kg resulted in a dose-dependent prolongation of activated partial thromboplastin time (APTT). The transient APTT prolongation in a subset of nonhuman primates was temporally associated with an immune response to hFVIII-SQ protein. At 3 months post-administration, histopathology findings included minimal to mild mononuclear/mixed infiltration in the lungs."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 8 mL Vial Label NDC 68135-927-01 Rx only valoctocogene roxaparvovec-rvox ROCTAVIAN™ Suspension for intravenous infusion 16 x 10 13 vector genomes/8 mL (2 x 10 13 vector genomes/mL) BioMarin Pharmaceutical Inc. Novato, CA 94949 US License No. 1649 Single-dose Discard unused portion BiOMARIN ® PRINCIPAL DISPLAY PANEL - 8 mL Vial Label","PRINCIPAL DISPLAY PANEL - 8 mL Vial Carton Rx only NDC 68135-927-48 valoctocogene roxaparvovec-rvox ROCTAVIAN™ Suspension for intravenous infusion 16 x 10 13 vector genomes/8 mL (2 x 10 13 vector genomes/mL) Contains one single-dose vial. BiOMARIN ® PRINCIPAL DISPLAY PANEL - 8 mL Vial Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No animal studies have been conducted to evaluate the effects of ROCTAVIAN on carcinogenesis. To evaluate vector integration, host genomic DNA was isolated from liver tissues obtained from nonhuman primates at 13 and 26 weeks following intravenous administration of ROCTAVIAN at dose levels of up to 5.4 × 10 13 vg/kg. Vector DNA was mostly detected in the form of episomal DNA that was not integrated into the host genome. Vector integration events were observed at low frequencies and distributed throughout the host genome with no indication of clonal enrichment or preference to particular chromosomal locations, including genes associated with oncogenesis in humans [see Warnings and Precautions (5.5) and Clinical Pharmacology (12.2) ] . Since ROCTAVIAN vector DNA was detected in testes of adult male mice for at least 6 months following a single intravenous administration at dose level of 2.1 × 10 14 vg/kg [see Clinical Pharmacology (12.3) ] , the potential for vertical transmission to offspring was studied in Rag2-/- immunodeficient mice. A single intravenous administration of ROCTAVIAN at a dose level of 6.7 × 10 13 vg/kg into male immunodeficient mice that were mated 37 days later with naïve female mice did not result in adverse effects on fertility rates, pregnancy rates, and litter sizes. Quantitative polymerase chain reaction (qPCR) evaluation of liver tissues from the F1 pups did not detect the vector DNA."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Severe hereditary factor VIII deficiency disease","category":"indication"},{"label":"BioMarin International Limited","category":"company"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"ALANINE AMINOTRANSFERASE INCREASED","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"FACTOR VIII ACTIVITY DECREASED","source":"FDA FAERS","actionTaken":"4 reports"},{"date":"","signal":"HAEMORRHAGE","source":"FDA FAERS","actionTaken":"3 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"TRAUMATIC HAEMORRHAGE","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"ASPARTATE AMINOTRANSFERASE INCREASED","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"CD4 LYMPHOCYTES INCREASED","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"EXTRADURAL HAEMATOMA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1 reports"}],"commonSideEffects":[{"effect":"ALT increases ULN","drugRate":"81%","severity":"serious","_validated":true},{"effect":"AST increases ULN","drugRate":"69%","severity":"serious","_validated":true},{"effect":"LDH increases ULN","drugRate":"57%","severity":"serious","_validated":true},{"effect":"CPK increases ULN","drugRate":"45%","severity":"serious","_validated":true},{"effect":"Factor VIII activity levels ULN","drugRate":"28%","severity":"serious","_validated":true},{"effect":"GGT increases ULN","drugRate":"18%","severity":"serious","_validated":true},{"effect":"Bilirubin increases ULN","drugRate":"13%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"31%","severity":"common","_validated":true},{"effect":"Fatigue","drugRate":"16%","severity":"common","_validated":true},{"effect":"Infusion-related reactions","drugRate":"7%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"7%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"6%","severity":"common","_validated":true},{"effect":"Abdominal pain","drugRate":"6%","severity":"common","_validated":true},{"effect":"Diarrhea","drugRate":"4%","severity":"common","_validated":true},{"effect":"Dizziness","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Rash","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Gastroenteritis","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Anaphylaxis","drugRate":"1%","severity":"serious","_validated":true},{"effect":"Hypersensitivity reaction","drugRate":"1%","severity":"serious","_validated":true},{"effect":"Presyncope","drugRate":"reported","severity":"unknown"},{"effect":"Cushingoid","drugRate":"reported","severity":"unknown"},{"effect":"Mood disorders","drugRate":"reported","severity":"unknown"},{"effect":"Acne","drugRate":"reported","severity":"unknown"},{"effect":"Insomnia","drugRate":"reported","severity":"unknown"},{"effect":"Weight gain","drugRate":"reported","severity":"unknown"},{"effect":"Hypertension","drugRate":"reported","severity":"unknown"},{"effect":"Folliculitis","drugRate":"reported","severity":"unknown"},{"effect":"Vision disorders","drugRate":"reported","severity":"unknown"},{"effect":"Bone fracture","drugRate":"reported","severity":"unknown"}],"contraindications":["Active infection","Cirrhosis of liver","Hepatic fibrosis"],"specialPopulations":{"Pregnancy":"ROCTAVIAN is not intended for administration in women. There are no data on the use of ROCTAVIAN in pregnant women to inform drug-associated risk of adverse developmental outcome. Animal reproduction and developmental toxicity studies have not been conducted with ROCTAVIAN. It is not known whether ROCTAVIAN can cause fetal harm when administered to pregnant woman or can affect reproduction capacity.","Geriatric use":"Clinical studies of ROCTAVIAN did not include sufficient numbers of patients aged 65 and over to determine whether the efficacy or safety differs compared to younger patients.","Paediatric use":"The safety and effectiveness of ROCTAVIAN in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"BioMarin International Limited","patents":[{"type":"Biologic Exclusivity","filed":"June 29, 2023","source":"FDA Purple Book","status":"Active","expires":"June 29, 2030","territory":"US","patentNumber":"BLA 125720"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VALOCTOCOGENE ROXAPARVOVEC","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:42:13.162528+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:42:13.162424+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Valoctocogene Roxaparvovec","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:42:19.772663+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:42:18.387292+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:42:13.229427+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VALOCTOCOGENE ROXAPARVOVEC","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:42:18.719400+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:42:11.840200+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:42:11.840222+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:42:20.186375+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor IX exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:42:19.772591+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297579/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:42:19.425422+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA125720","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:42:11.840226+00:00"}},"allNames":"roctavian","offLabel":[],"synonyms":["valoctocogene roxaparvovec","BMN270","roctavian"],"timeline":[{"date":"2022-08-24","type":"positive","source":"DrugCentral","milestone":"EMA approval (BioMarin International Limited)"}],"aiSummary":"Roctavian (valoctocogene roxaparvovec) is a gene therapy developed by BioMarin International Limited for the treatment of severe hereditary factor VIII deficiency disease. It works by introducing a functional copy of the F8 gene into the patient's cells, allowing them to produce factor VIII protein. Roctavian is currently patented and has been approved by the FDA for its intended use. Key safety considerations include the risk of insertional mutagenesis and the potential for immune responses against the vector. In plain terms, Roctavian helps patients with severe factor VIII deficiency by giving their cells the instructions to make the missing protein.","approvals":[{"date":"2022-08-24","orphan":true,"company":"BioMarin International Limited","regulator":"EMA"}],"brandName":"Roctavian","ecosystem":[{"indication":"Severe hereditary factor VIII deficiency disease","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"Valoctocogene roxaparvovec-rvox is an adeno-associated virus serotype (AAV5) based gene therapy vector, designed to introduce functional copy of transgene encoding the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). Transcription of this transgene occurs within the liver, using liver-specific promoter, which results in the expression of hFVIII-SQ. The expressed hFVIII-SQ replaces the missing coagulation factor VIII needed for effective hemostasis.","oneSentence":"Roctavian introduces a functional copy of the F8 gene into cells to produce factor VIII protein.","technicalDetail":"Roctavian is a recombinant adeno-associated virus (rAAV) vector that delivers a functional copy of the F8 gene to the liver, where it is then expressed and secreted into the bloodstream as functional factor VIII protein."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Valoctocogene_roxaparvovec","title":"Valoctocogene roxaparvovec","extract":"Valoctocogene roxaparvovec, sold under the brand name Roctavian, is a gene therapy used for the treatment of hemophilia A. It was developed by BioMarin Pharmaceutical. Valoctocogene roxaparvovec is made of a virus (AAV5) that has been modified to contain the gene for factor VIII, which is lacking in people with hemophilia A. It is an adeno-associated virus vector-based gene therapy. It is given by intravenous infusion.","wiki_history":"== History ==\nThe US Food and Drug Administration (FDA) granted valoctocogene roxaparvovec orphan drug status in 2016, and breakthrough therapy designation in 2017. \n\nHowever, in August 2020, BioMarin received a Complete Response Letter from the FDA, indicating that its Biologics License Application (which would have made valoctocogene roxaparvovec the first gene therapy to be approved for a bleeding disorder) would not be approved. The regulator was concerned that differences between results from the phase I/II trials (the 270-201 study) and the phase III trial (the 270-301 study) were too dissimilar with regard to durability, the latter suggesting that the protective effect of valoctocogene roxaparvovec wore off after approx. 12-18 months.\n\nThe safety and effectiveness of valoctocogene roxaparvovec were evaluated in a multinational study in adult men 18 to 70 years of age with severe hemophilia A who were previously treated with factor VIII replacement therapy. Effectiveness was established based on results from a cohort of 112 participants followed up for at least 3 years after valoctocogene roxaparvovec treatment. Following the infusion, the mean annualized bleeding rate decreased from 5.4 bleeds per year at baseline to 2.6 bleeds per year. The majority of participants who received valoctocogene roxaparvovec received corticosteroids to suppress the immune system for the gene therapy to be effective and safe. The FDA granted the application for valoctocogene roxaparvovec orphan drug, breakthrough therapy, regenerative medicine advanced therapy, and priority review designations. The FDA granted approval of Roctavian to BioMarin Pharmaceutical Inc.","wiki_society_and_culture":"== Society and culture ==\n=== Legal status ===\nOn 23 June 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Roctavian, intended for the treatment of severe haemophilia A. Valoctocogene roxaparvovec was approved for medical use in the European Union in August 2022.\n\nIn June 2023, the US FDA approved valoctocogene roxaparvovec for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test."},"commercial":{},"purpleBook":{"bla":"125720","source":"FDA Purple Book","approvalDate":"June 29, 2023","licenseStatus":"Licensed","exclusivityExpiry":"June 29, 2030"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5705","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VALOCTOCOGENE%20ROXAPARVOVEC","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VALOCTOCOGENE ROXAPARVOVEC","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Valoctocogene_roxaparvovec","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://purplebooksearch.fda.gov/","fields":["biologicExclusivity"],"source":"FDA Purple Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T16:07:24.309390","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:42:23.026810+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","company":"BioMarin Pharmaceutical Inc.","brandName":"ROCTAVIAN","isOriginal":"","marketingStatus":"BLA"}],"competitors":[],"genericName":"valoctocogene roxaparvovec","indications":{"approved":[{"name":"Severe hereditary factor VIII deficiency disease","source":"DrugCentral","snomedId":16872008,"regulator":"FDA","eligibility":{"age":"adults","stage":"severe hemophilia","biomarkers":"congenital factor VIII deficiency with factor VIII activity 1 IU/dL","prior treatment":"without antibodies to adeno-associated virus serotype (AAV5) detected by an FDA-approved test"}}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06224907","phase":"PHASE3","title":"Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2023-12-25","conditions":["Hemophilia A"],"enrollment":6,"completionDate":"2029-03"},{"nctId":"NCT04323098","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2020-12-08","conditions":["Hemophilia A"],"enrollment":22,"completionDate":"2025-05-08"},{"nctId":"NCT03520712","phase":"PHASE1,PHASE2","title":"Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5","status":"TERMINATED","sponsor":"BioMarin Pharmaceutical","startDate":"2018-04-24","conditions":["Hemophilia A","Gene Therapy","Clotting Disorders","Blood Disorder"],"enrollment":3,"completionDate":"2024-08-07"},{"nctId":"NCT04684940","phase":"PHASE1,PHASE2","title":"Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2020-12-10","conditions":["Hemophilia A With Inhibitor","Hemophilia A With Anti Factor VIII"],"enrollment":10,"completionDate":"2029-04"},{"nctId":"NCT02576795","phase":"PHASE1,PHASE2","title":"Gene Therapy Study in Severe Haemophilia A Patients (270-201)","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2015-09-28","conditions":["Severe Haemophilia A"],"enrollment":15,"completionDate":"2024-02-14"},{"nctId":"NCT03370913","phase":"PHASE3","title":"Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2017-12-19","conditions":["Hemophilia A"],"enrollment":144,"completionDate":"2024-11-20"},{"nctId":"NCT03392974","phase":"PHASE3","title":"Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2018-03-14","conditions":["Hemophilia A"],"enrollment":1,"completionDate":"2023-06-05"}],"_emaApprovals":[{"date":"2022-08-24","status":"Authorised","company":"BioMarin International Limited"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"ROCTAVIAN"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"41769","UNII":"681K1JDI8M","INN_ID":"10463","RXNORM":"2641610","UMLSCUI":"C4726937","chemblId":"CHEMBL4297579","ChEMBL_ID":"CHEMBL4297579","KEGG_DRUG":"D12434","DRUGBANK_ID":"DB15561","MESH_SUPPLEMENTAL_RECORD_UI":"C000723395"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"BioMarin International Limited","relationship":"Original Developer"}],"publicationCount":74,"therapeuticAreas":["Rare Disease"],"_revenueScrapedAt":"2026-03-31 09:37:14.404209+00","biosimilarFilings":[],"originalDeveloper":"BioMarin International Limited","recentPublications":[{"date":"2026 Mar 12","pmid":"41818413","title":"Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels.","journal":"Haemophilia : the official journal of the World Federation of Hemophilia"},{"date":"2026","pmid":"41773269","title":"Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.","journal":"Journal of blood medicine"},{"date":"2026 Feb 25","pmid":"41709782","title":"Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.","journal":"Expert review of hematology"},{"date":"2026 Jan","pmid":"41549917","title":"Balancing Promise and Peril: Hemophilia Gene Therapy Insights.","journal":"IUBMB life"},{"date":"2026 Mar","pmid":"41448545","title":"Overview of gene therapy for hemophilia: questions and answers to navigate the innovation.","journal":"Journal of thrombosis and haemostasis : JTH"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"BioMarin International Limited","companyId":"biomarin","modality":"Gene therapy","firstApprovalDate":"2022","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2022-08-24T00:00:00.000Z","mah":"BioMarin International Limited","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2022-08-24T00:00:00.000Z","mah":"BioMarin International Limited","brand_name_local":"Roctavian","application_number":"EMEA/H/C/005830"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":"BioMarin International Limited","brand_name_local":"Roctavian","application_number":"EMEA/H/C/004749"}],"trialStats":{"total":2,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:42:23.026810+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}